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Bovine Infected Cell Protein 0 (bICP0) is an immediate-early protein encoded by
Bovine Herpesvirus-1 that modulates host immune response, activates transcription for
all viral promoters, and causes ubiquitin-dependent degradation of proteins. Presented
herein is a bICP0 protein-protein interaction (PPI) profile, consisting of 98 cellular and
15 viral proteins, generated through co-immunoprecipitation of bICP0 and its binding
partners. The PPI profile was analyzed computationally to identify potential sites of
interaction with bICP0 and any cellular pathways that may be influenced by bICP0.
Some interactors fall in conjunction with bICP0’s known roles during infection,
and others are consistent with known associations of bICP0 homologs. However, some
proteins in the PPI profile are involved in apoptosis signaling and mRNA spicing—
processes both significant during viral infection and novel to the known functions of
bICP0 and its homologs. The interaction and co-localization of some of these proteins
with bICP0 was further examined.
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INTRODUCTION

Bovine Herpesvirus-1 (BHV-1) is an α-herpesvirus that primarily infects bovine
species. In adults, BHV-1 infection is generally mild, but active infection of pregnant
cows can cause abortions and infection can be deadly for calves. BHV-1 can also cause
the manifestation of the Bovine Respiratory Disease Complex (BRDC) by lowering the
capacity of the host’s immune system to fight disease and allowing opportunistic
infections to take hold (Clinton Jones & Chowdhury, 2010). These secondary infections,
combined with loss in weight/body condition, decreased milk yield, and treatmentassociated costs, cause an estimated economic loss up to $3 billion dollars yearly for the
American cattle industry (Clinton Jones & Chowdhury, 2007; Muylkens, Thiry, Kirten,
Schynts, & Thiry, 2007). Furthermore, a 2009 study found that the economic losses
associated with BRDC steadily increased after subsequent treatments (i.e., some cattle
under study suffered from recurring outbreaks the disease, and each outbreak was
indirectly recorded as the number of treatments the animal received) (Schneider, Tait,
Busby, & Reecy, 2009).
The BHV-1 life cycle consists of two distinct stages, lytic replication and latency.
Primary infection is established in the mucosal tissues where the virus actively replicates;
this is associated with symptoms of disease in the infected animal. Transcription of viral
genes occurs in a temporal cascade of events beginning with the immediate-early, then
1

early, and then late genes. Upon translation of the late gene products, new virions are
assembled in the cell and transverse to the cellular membrane where they bud off and can
proceed to infect new cells. From this primary site of infection, the virus migrates to
infect peripheral neurons where it establishes latency in the body of neurons residing in
either the trigeminal or sacral ganglia (Nandi, Kumar, Manohar, & Chauhan, 2009).
During latency, there is no viral replication and the animal does not show any clinical
signs of infection. However, stress can reactivate the virus, and it will switch back to the
lytic stage where the virus will travel back to the primary site of infection and again begin
actively replicating. It is important to note that only during lytic replication is the virus
infectious and the host manifests clinical symptoms (Muylkens et al., 2007).
Bovine Infected Cell Protein 0 (bICP0) is a 676 amino acid protein expressed as
an immediate-early gene of BHV-1. It is homologous to ICP0 in Herpes Simplex Virus-1
(HSV-1) and Equine Herpesvirus-1 (EHV-1) (Boutell & Everett, 2013). The protein
structure consists of four important functional domains: a C3HC4 zinc RING (Really
Interesting New Gene) finger at the N-terminus, two transcriptional activation domains
(TADs), and a nuclear localization sequence (NLS) at the C-terminus. There is also an
acidic domain, which is commonly found in proteins with TADs, but no activity has been
found to be associated with it (Y. Zhang, Zhou, & Jones, 2005). The RING finger of
bICP0 is most vital for promotion of productive infection and has different roles toward
that effect (Saira et al., 2008). Interestingly, the RING finger is the only point of
similarity between bICP0 and its homologs in Herpes Simplex Virus-1 (ICP0) and other
alphaherpesviruses (Boutell & Everett, 2013). bICP0 is constantly expressed at high
levels during productive infection, which can be attributed to an early, self-regulated
2

promoter, as well as its immediate-early promoter (Fraefel et al., 1994). Its presence
during infection has been demonstrated to significantly bolster productive infection
(Geiser, Zhang, & Jones, 2005). Previous studies transfecting bICP0 alone have found it
to be cytotoxic to cell cultures, and in the context of productive infection, bICP0 triggers
a delayed apoptotic response (Henderson, Zhang, Inman, Jones, & Jones, 2004;
Steinmann, Nuñez, Köppel, & Ackermann, 2014). In comparison to the wild type virus, a
bICP0-null mutant does not form plaques, appears to establish a type of persistent-like
infection, and produces viral titers 100-fold lower (Geiser et al., 2005).
Several studies have characterized how bICP0 can aid productive infection
through its overlapping activities as a transcription factor, regulator of interferon
response, and ubiquitin E3 ligase. In its role as a transcription factor, bICP0 has been
shown to activate all BHV-1 promoters, as well as some promoters of other viruses (Y.
Zhang & Jones, 2001). However, rather than directly binding with the DNA of the
promoter regions, instead bICP0 interacts with other factors in such a manner to
indirectly affect gene transcription. The first example was the identification of an
interaction between bICP0 and histone deacetylase-1 (HDAC-1), which correlated with a
relief in transcriptional repression and activation of a simple promoter (Y. Zhang &
Jones, 2001). bICP0 was later also shown to interact with p300, a histone
acetyltransferase; furthermore, this interaction was shown to augment productive
infection by increasing activation of viral promoters and inhibiting interferon-dependent
transcription (Y. Zhang, Jiang, Geiser, Zhou, & Jones, 2006). bICP0 is also known to
directly impede the interferon signaling by sequestering activated interferon regulatory
factor-7 (IRF-7) in PML bodies in the nucleus (Saira, Zhou, & Jones, 2009), and it also
3

induces the degradation of activated IRF-3 in its capacity as an ubiquitin E3 ligase (Saira,
Zhou, & Jones, 2007). Inhibiting the interferon response, which is part of the cellular
innate immune response, serves to only further enhance productive infection.
While previous research has discovered multiple roles for bICP0 during infection,
little is known of the specific interactions required to achieve the results observed. While
the four known interactors, described above (HDAC-1, p300, IRF-7, and IRF-3),
certainly help explain some of the effects attributed to bICP0 during infection, they do
not paint the entire picture. With that in mind, we have generated a protein-protein
interaction (PPI) profile by co-immunoprecipitation of bICP0 and its binding partners.
Using a custom-made antibody specific for bICP0, it and its protein interactors were
pulled out of solution and identified via mass spectrometry. A total of 98 cellular and 15
viral proteins were identified; functions of these putative interactors range from
transcription initiation and modulation of the host immune response to mRNA processing
and apoptosis. The experimental bICP0 PPI profile was computationally analyzed to
identify potential sites of interaction with bICP0 and cellular pathways that may be
influenced by bICP0, and the association of select interactors was further examined
experimentally via confocal microscopy and western blotting.
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CHAPTER II
LITERATURE REVIEW

2.1

BHV-1
Bovine Herpesvirus-1 (BHV-1) is a member of the Alphaherpesvirinae subfamily

of Herpesviridae and consists of a double-stranded linear DNA genome housed within
the nucleocapsid of the enveloped virion (Figure 2.1). As with other herpesviruses, there
is a matrix of tegument proteins packaged in the virion between the envelope and the
nucleocapsid; upon entry of the virus into a host cell, these proteins are immediately
available to aid productive infection before transcription of viral genes (Muylkens et al.,
2007).

Figure 2.1

Structure of a Herpesvirus Virion
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BHV-1 alternates between two distinct phases: lytic (or productive) replication
and latency. The initial infection in the host typically occurs in the oral, nasal, or ocular
mucosal epithelium. A few virions get access to nearby peripheral neurons and travel in a
retrograde manner to the body of the neuron, where latency is established in either the
trigeminal or sacral ganglia. During latency, there is very limited viral transcription and
no viral replication. Furthermore, the host exhibits no signs of clinical infection.
However, stress can reactivate the virus, and it will travel anterogradely to the site of
primary infection and enter the lytic replication phase. This cycle is endless and once
infected, the host will carry the virus for the remainder of its lifetime (Muylkens et al.,
2007).
2.1.2

Lytic Cycle
The lytic cycle begins with viral attachment and entry, then viral gene

transcription and replication, and concludes with assembly and release of progeny virions
(Figure 2.2). Attachment of α-herpesviruses to a permissive cell occurs through
interactions between viral glycoproteins and cellular surface receptors. In the case of
BHV-1, both glycoprotein C (gC) and gB can interact with heparin sulfate proteoglycans
(Herold, Visalli, Susmarski, Brandt, & Spear, 1994). Additional interactions take place
between gD and nectin-1; membrane fusion is induced and the virus enters the cell
(Connolly et al., 2001; Geraghty, Krummenacher, Cohen, Eisenberg, & Spear, 1998).
The nucleocapsid is then transported along a microtubule network to dock at the nucleus
(Sodeik, Ebersold, & Helenius, 1997), and the viral genome is released into the nucleus
where it soon circularizes (Fraefel, Wirth, Vogt, & Schwyzer, 1993; Garber, Beverley, &
Coen, 1993). Meanwhile, tegument proteins help ready the cell for viral infection. The
6

virion host shutoff (VHS) protein quickly disables cellular protein synthesis by degrading
mRNAs, and is a well-conserved protein amongst alphaherpesviruses (Hinkley,
Ambagala, Jones, & Srikumaran, 2000). Other tegument proteins, such as VP16,
translocate to the nucleus and activate the first wave of viral gene transcription
(Muylkens et al., 2007).
Herpesvirus gene transcription occurs in a temporal cascade of events where
expression of immediate-early (IE) genes, via the cellular RNA polymerase II, causes
transcriptional activation of the early (E) genes. These, in turn, activate the transcription
of the late (L) genes. IE genes are primarily concerned with gene transcription and
overcoming host defenses, and they activate transcription of the E genes. E genes encode
the specialized machinery for viral genome replication, while the L genes encode the
structural proteins of the virion, such as capsid and envelope proteins (Levings & Roth,
2013).
Soon after expression of E genes, viral DNA replication occurs, though the bulk
of viral replication occurs later into the infection. Since the genome is circularized at this
point, there is no need for specialized replication of the termini, and replication takes
place through two sequential phases, theta-replication and sigma-replication. Thetareplication begins at an origin of replication and proceeds in a bidirectional manner.
However, the mechanism of replication then switches to sigma-replication, also known as
the rolling circle—generating concatemers of the viral genome. Cleavage of the
concatemer into individual genomes occurs after capsid packaging (Boehmer & Lehman,
1997).
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Capsid assembly and packaging of viral DNA occurs within the nucleus of the
infected cell, but the final assembly takes place in the cytoplasm. There have been a
number of different hypotheses on how mature capsids exit the nucleus for final
assembly, since the cell’s usual trafficking of proteins and other molecules through the
nuclear pores is not a viable option given the pores’ size limitations. However, it is now
known to occur via a process known as nuclear egress (Mettenleiter, Müller, Granzow, &
Klupp, 2013). The mature capsid buds from the inner nuclear membrane into the
perinuclear space followed by fusion with the outer nuclear membrane, releasing the
capsid into the cytoplasm (Skepper, Whiteley, Browne, & Minson, 2001). Once in the
cytoplasm, tegument proteins are assembled around the capsid and an envelope is
acquired through budding from a Golgi compartment (Muylkens et al., 2007).

Figure 2.2

The Herpesvirus Lytic Cycle
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2.1.3

Latency and Reactivation
During productive infection, the herpesvirus spreads to infect other neighboring

cells and tissues, including peripheral neurons. In neuronal cells the virus shifts to a
second phase in its life cycle: latency. Latency is noted for the absence of both lytic gene
expression and viral genome replication. Instead, there is a high expression of latency
associated transcripts (LATs) (C Jones et al., 2006; D. L. Rock, Beam, & Mayfield,
1987). Once latency is established, it will be maintained for the lifetime of the host.
Nonetheless, BHV-1 can be reactivated from latency in response to external stimuli, such
as stress, other active infections, or in response to dexamethasone (Muylkens et al., 2007;
D. Rock, Lokensgard, Lewis, & Kutish, 1992). Upon reactivation, there is rapid
reappearance of lytic gene expression, viral replication is initiated, and BHV-1 can
disseminate to infect other cells. Because there is no viral replication during latency,
hosts harboring the latent virus cannot spread the infection to other individuals. Only
upon reactivation is infectious virus produced and able to disseminate in the population
(Clinton Jones, 2003).
2.1.4
2.1.4.1

Epidemiology of BHV-1 Infections
Susceptible Hosts
Domestic and wild cattle are the primary hosts of BHV-1, but the virus can also

infect goats, sheep, water buffaloes, and camels (Beer, 2010). The risk factors for
acquiring BHV-1, as determined by seroprevalence studies in cattle, are the age and sex
of the individual animal as well as the size of the herd (Boelaert et al., 2005).
Additionally, calves have a much higher fatality rate associated with the virus than adults
due to their underdeveloped immune system (Clinton Jones & Chowdhury, 2010).
9

Interestingly, a 2005 study found that bulls appear to be significantly more susceptible to
BHV-1 infection than cows by a factor of 1.37. It is conjectured that this difference could
be attributed to an increased probability of contact with an infected animal, such as
participating in cattle shows and escaping pens to mingle with other cattle (Boelaert et al.,
2005).
2.1.5
2.1.5.1

Clinical Symptoms
IPV/IPB
Infectious pustular vulvovaginitis/infectious pustular balanoposthitis (IPV/IPB) is

more commonly seen in breeding cattle. IPV is characterized by frequent urination,
vaginal infection, swelling of the vulva, and ulcerations on the surface of the mucosal
tissue; likewise, bulls with IPB have comparable lesions on the penis and prepuce. The
recovery period is usually 2 weeks after onset of infection, which usually occurs within 1
to 3 days after mating. Secondary infections can further complicate IPV/IPB in afflicted
animals; this can lead to inflammation of the uterus and affect fertility (Clinton Jones &
Chowdhury, 2007).
2.1.5.2

IBR
Historically, BHV-1 infections have manifested as IPV/IPB; however, beginning

in the 1950s a new form of the infection arose in the United States, infectious bovine
rhinotracheitis (IBR). IBR is now the most predominant and virulent syndrome of BHV-1
infection worldwide and caused by the BHV-1.1 subtype (Muylkens et al., 2007).
Characterized by mucoid nasal discharge, hyperemia of the muzzle, and
conjunctivitis, IBR is most commonly seen in feedlot cattle (Beer, 2010; Clinton Jones &
10

Chowdhury, 2007). BHV-1.1 incubation period is 2 to 6 days, with a typical recovery by
4 to 5 days after clinical symptoms appear (Clinton Jones & Chowdhury, 2007).
Generally, IBR produces a low mortality rate and most infections are subclinical.
However, secondary infections can take advantage of IBR-induced immune suppression
and can lead to the development of the bovine respiratory disease complex (BRDC), also
known as shipping fever.
2.1.5.3

BRDC
BRDC is a condition that arises from the interaction of several pathogens with the

host. BHV-1 is believed to be one of the initiation factors, because it decreases cellmediated immunity in infected individuals, and this permits opportunistic pathogens,
such as the bacteria Mannheimia haemolytica and Haemophilus somnus, to flourish
(Clinton Jones & Chowdhury, 2007). BRDC presents a particular risk for feedlot cattle,
since the stress and close confines of shipping promote the development and spread of
BRDC and causes significant economic losses by loss of body condition (Nandi et al.,
2009).
2.1.6

Transmission
BHV-1 is rapidly transmitted through a herd through direct contact with an

infected animal. In the case of IBR, the virus is shed in high titers in the nasal secretions
and can contaminate fomites, such as shared feeding troughs. Coughing can cause
aerosolization of virus and presents another avenue of transmission (Nandi et al., 2009).
IPV/IPB is transmitted by sexual contact or contaminated semen. In the case of the latter,
the virus is carried not in the spermatozoa but in the seminal plasma, and presents a
11

particular problem for artificial insemination (AI). While transmission by natural mating
can cause temporary infertility, studies have suggested that transmission by AI can cause
more detrimental effects to the cow, such as shorter estrus cycles, decreased pregnancy
rates, and endometritis (van Oirschot, 1995).
2.1.7

Prevalence
BHV-1 infections in cattle are endemic worldwide. Certain subtypes can be more

prevalent in some geographical areas than others. Subtype 1.1 is associated with the
Americas and Europe, subtype 2a with Brazil and Europe (prior to the 1970s), and
subtype 2b with Australia and Europe (Clinton Jones & Chowdhury, 2007).
Seroprevalence ranges from very high in the United States, Canada, Australia, and New
Zealand to a low presence in some European countries (Ackermann & Engels, 2006).
2.1.8

Diagnostic Tests
Diagnostic tests are not always accurate and sometimes may not be able to

distinguish between naturally infected and vaccinated cattle. While most diagnostics are
highly specific for animals acutely infected with BHV-1, sensitivity of these tests can
pose a problem for detection (i.e., the probability of a false positive is low, but the
probability of a false negative may be high), especially for latent infections (Table 1).
Virus isolation alone may not be a good standard, because other related
alphaherpesviruses can be mistaken for BHV-1 (e.g., BHV-5). Therefore, only PCR can
definitively confirm the presence of BHV-1 in a sample. It is also recommended to use
multiple tests for more accurate detection of BHV-1 positive cattle (Beer, 2010).
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Table 2.1

Comparison of Different BHV-1 Diagnostic Tests

Routine
Time
Detection of
Sensitivity Specificity
Sample Type Required
Latent Carriers?
Nasal Swab,
Days
Virus Isolation
Low
High
No
Semen
to Weeks
Yes (Postmortem
Sensory
Sensory Ganglia);
PCR
Ganglia,
A Day
High
High
No (Semen
Semen
Samples)
Antigen
Nasal, Ocular, Hours
Low
High
No
Detection
Genital Swabs to a Day
Hours
Moderate/
Serological Test
Blood
High
Maybe
to a Day
High
Note: Based on the World Organisation for Animal Health (OIE) Terrestrial Manual
(Beer, 2010).
Diagnostic Test

2.1.9

Control Measures
BHV-1 is endemic in the worldwide cattle population (Clinton Jones &

Chowdhury, 2007). Due to its inherent nature, latent viral infections are difficult to detect
and these silent carriers can pose issues for control. Efforts at eradication have thus far
only been successful in countries with a small cattle population. A country’s BHV-1-free
status can be advantageous in international trade, however it also brings with it the
constant threat of outbreak from outside its borders. Case-in-point, Switzerland has
eradicated BHV-1 since 1993; yet by 2006, there were 29 confirmed cases—all of which
originated with either the importation of latent carriers or infected semen. In countries
with large cattle populations where infection is endemic, like the United States,
eradication is simply not feasible (Ackermann & Engels, 2006; Clinton Jones &
Chowdhury, 2007). Instead, these countries must rely heavily on vaccination programs to
minimize the economic losses associated with BHV-1 infections (Turin, Russo, & Poli,
1999).
13

2.1.9.1

Vaccines
In the United States, cattle are regularly immunized with an anti-BRDC vaccine

and adjuvant, which targets BHV-1 as well as other pathogens and produces an active
immune response. In fact, if there is a suspected outbreak of IBR, most cattle operations
will vaccinate again to prevent the spread of wild-type virus (Muylkens et al., 2007).
Modified-live and inert vaccines are classic vaccination strategies. Modified-live
vaccines are composed of attenuated virus that is still infectious, but causes a much
milder form of the disease (in some cases it may not cause clinical signs at all). This
natural route of infection encourages development of a strong immune response in the
animal. However, these vaccines are capable of establishing latency and there is a risk of
the virus later reactivating and regaining virulence. Inert vaccines refer to those
composed of inactivated virus or just viral subunits and, consequently, safer alternatives
to vaccination. Yet, since there is no active infection occurring, they produce a much
weaker immune response (Muylkens et al., 2007). Both modified-live and inert vaccines
have engineered markers in them to help differentiate infected from vaccinated animals in
diagnostic tests. Promisingly, studies have shown that these marker vaccines can
effectively reduce signs of BHV-1 infection and decrease wild-type virus replication and
transmission (Turin et al., 1999), but there is concern of recombination between wildtype virus and marker vaccines that could produce a new virulent strain that will render
the purpose of the marker moot (Muylkens et al., 2007).
2.2

Comparison of bICP0 to ICP0 in HSV-1
BHV-1’s bICP0 is functionally homologous to ICP0 of Herpes Simplex Virus-1

(HSV-1); moreover, homologs of ICP0 have been found in all studied
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alphaherpesviruses, including Equine Herpesvirus-1, Varicella-Zoster Virus, and
Pseudorabies Virus (Everett, Boutell, McNair, Grant, & Orr, 2010; Parkinson & Everett,
2000). Protein homology is fairly restricted to the RING domain, which has ubiquitin E3
ligase activity; however, numerous mutational studies have shown this domain to be vital
to most of the proteins’ activities (Parkinson & Everett, 2001).
Comparison analyses of this family of ICP0 proteins have suggested they all
employ a similar, intrinsic strategy to target the same or similar pathways, even while the
individual proteins targeted by each ICP0 homolog may not all be congruent—suggesting
that such variances may have arisen as a result to biological differences amongst hosts
(Parkinson & Everett, 2000). Furthermore, a study complementing an ICP0-null mutant
HSV-1 virus with bICP0 found it capable of restoring plaque formation, aiding viral
reactivation from latency, and replicating most other known phenotypes of ICP0
expression during normal infection (Roger D Everett et al., 2010). This supports the
notion that research on one homolog can be highly applicable for another, and if not
validating a reported association, at least validating an influence on a common pathway.
Of these various homologs, HSV-1’s ICP0 has been studied most extensively.
ICP0 was initially recognized as a promiscuous transactivator, capable of inducing
transcription of a variety of genes (viral and host) without a cis-acting element. Largely
associated with the nucleus, ICP0 can also be found in the cytoplasm at late stages of
infection. In the nucleus, ICP0 is chiefly associated with PML bodies. As will be
discussed later, increased expression of PML bodies is part of the innate and intrinsic
immune responses to viral infection (Regad & Chelbi-Alix, 2001). Thus, it is no surprise
that ICP0 targets PML and other constituents of the PML bodies for degradation (Roger
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D Everett & Chelbi-Alix, 2007; Roger D Everett et al., 2006). Like bICP0, ICP0 is also
known to associate with chromatin remodeling complexes to regulate gene transcription,
including several class II histone deacetylases (Coleman et al., 2008; Patrick Lomonte et
al., 2004). While chiefly associated with the nucleus, ICP0 has also been found in the
cytoplasm at later points during infection, although this appears to be more of a transient
behavior than a permanent redistribution (Hagglund & Roizman, 2004).
2.2.1

Chromatin Biology
Chromatin consists of the orderly and repeated wrapping of DNA around a

complex of 8 histone proteins, or nucleosomes. Chromatin not only serves to compact
DNA in an orderly manner, but at its most basic level, structurally, it also exerts control
on gene transcription. There are two classifications of chromatin based upon its level of
organization: euchromatin and heterochromatin. Euchromatin consists of evenly spaced
nucleosomes with stretches of extended DNA between, like beads on a string.
Heterochromatin is more compact, where the nucleosomes themselves are organized into
a more dense fiber. The openness of the euchromatin structure promotes expression of the
genes between nucleosomes by keeping transcription factor binding sites accessible;
furthermore, the loose structure also allows some repositioning of the histones along the
DNA strands. By contrast, heterochromatin is associated with gene repression, since
those stretches of the chromatin are wound too tightly to allow access for transcription
factors (Clapier & Cairns, 2009).
In the cell, the chromatin exists in dynamic expanses of both euchromatin and
heterochromatin, where exact composition depends upon the current needs of the cell.
Responsible for packaging and subsequent alterations of the chromatin landscape are the
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chromatin remodeling enzymes. These remodelers achieve their effect via posttranslational modification of the N-terminal tail of the histone proteins. Combinations of
acetylation, methylation, phosphorylation, and ubiquitination affect the strength of
association between histone proteins and DNA (and thus the availability of the gene in
question) and/or cause the recruitment of other factors, ultimately regulating gene
expression. In general, acetylation is considered to promote gene expression, while
methylation is associated with gene silencing. These modifications are carefully balanced
by opposing classes of enzymes that add or remove these epigenetic marks (Selvi &
Kundu, 2009).
2.2.2

Chromatinization of Herpesvirus Genomes
There are three chromatin states of the herpesvirus genome depending upon the

particular stage of the viral replication cycle. Chromatin structure of herpesvirus genomes
also affects functionality (Knipe & Cliffe, 2008; Paulus, Nitzsche, & Nevels, 2010). In
the extracellular virion, space is a valuable commodity and the apparent lack of histone
proteins supports this idea that the DNA is not chromatinized (Oh & Fraser, 2008;
Pignattii & Cassai, 1980). Examination of HSV-1 virions have shown regularly spaced
polyamines balancing the negatively charged DNA (Gibson & Roizman, 1971). During
lytic infection, and the deposition of the viral DNA into the nucleus, the genome is
believed to maintain a reduced nucleosome state, compared to the host’s DNA (Leinbach
& Summers, 1980; Muggeridge & Fraser, 1986; Oh & Fraser, 2008). This unbound
structure promotes viral gene transcription, and in fact certain viral proteins have been
demonstrated to negatively regulate the nucleosome load (Knipe & Cliffe, 2008). For
example, ICP0 of HSV-1 is known to cause a decrease in histone association with the
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viral DNA (Cliffe & Knipe, 2008). Furthermore, during productive infection
nucleosomes associated with lytic genes acquire histone modifications that promote an
euchromatin structure that corresponds to active viral gene transcription (Kent et al.,
2004; Paulus et al., 2010). Studies on the chromatin state of latent herpesviruses found
regularly spaced histones, similar to cellular chromatin (Deshmane & Fraser, 1989).
Taken as a whole, these studies describe a viral balancing act, where chromatinization is
a key to controlling the various stages of infection.
On the other side of the equation, chromatinization of the viral genome by the
host can also serve as a defense mechanism for the cell by silencing the expression of
viral genes (Knipe & Cliffe, 2008). As an intrinsic response to infection, promyelocytic
leukemia (PML) bodies (described in more detail later) co-localize with and chromatinize
the viral genome into a repressive, heterochromatin structure (Paulus et al., 2010). To
counteract this cellular response, herpesviruses employ a combination of several
strategies; the following examples are within the context of HSV-1 infection. For
example, ICP0 has been shown to degrade PML and other proteins involved in chromatin
assembly, such as centromere protein A (CENP-A) (P Lomonte, Sullivan, & Everett,
2001). ICP0-null mutant viruses have severely hampered replication rates, and this
correlates with observations of increased nucleosome content of the viral genome (Paulus
et al., 2010). ICP0 also has a role in modulating histone modification through its
associations with histone remodeling complexes (Cliffe & Knipe, 2008; Knipe & Cliffe,
2008). Another viral protein, VP22, has also been found to inhibit formation of
nucleosomes on viral DNA (van Leeuwen, 2003). Finally, VP16, the main activator of IE
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genes, also affects chromatin structure by recruiting the histone deacetylase p300 (Knipe
& Cliffe, 2008).
2.3

Type I Interferon Response and α-Herpesviral Infections
In an innate response to viral infection, type I interferon (IFN), a class of secreted

cytokines, is produced to promote an antiviral state in the infected and neighboring cells.
While IFN is essential to mount an antiviral defense (Hwang et al., 1995), the cell cannot
afford to continuously produce IFN since it is detrimental to normal function. Detection
of a viral infection begins with the recognition of pathogen-associated molecular patterns
(PAMPs) by pathogen recognition receptors (PRRs), such as Toll-like receptors. Once a
PRR is stimulated, it recruits an adaptor molecule, like MyD88, which then activates a
chain reaction of events leading to induction of particular IFN genes. For IFN-β
induction, several transcription factors complexes are required, including NF-κB and
IRF-3. Both transcription factors are normally found in the cytoplasm, but in response to
viral infection, they become activated, dimerize, and translocate to the nucleus and bind
to the IFN-β promoter (Randall & Goodbourn, 2008). IFN is expressed and secreted to
bind to IFN receptors located on the cellular surface of both the originating cell and
neighboring cells. This activates the Janus kinase-signal transducer and activator of
transcription (JAK-STAT) pathway, leading to the induction of the many IFN-stimulated
genes (ISGs) and consequential establishment of the anti-viral state. The cellular antiviral state is a combination of hundreds of genes acting in concert; examples include
PML bodies and apoptosis that both hinder viral replication and are described in detail
later. Additionally, there is crosstalk within this system, such that some factors involved
in IFN-induction are, themselves, induced by IFN, amplifying the IFN response. An
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example is IRF-7. While IRF-3 is constitutively expressed, IRF-7 is undetectable in
uninfected cells. Instead, IRF-7 expressed as a result of the IFN receptor/JAK-STAT
pathway, like other ISGs. Once expressed, IRF-7 then works as part of a positive
feedback mechanism to activate the IFN-α genes (Katze, He, & Gale, 2002; Randall &
Goodbourn, 2008). Figure 2.3 outlines the IFN induction and response pathways.

Figure 2.3

Interferon Induction and Signaling

In response to this innate cellular response, α-herpesviruses have developed
several countermeasures. HSV-1 and BHV-1 encode several such genes, including
ICP0/bICP0, virion host shutoff (VHS), and Us3. As previously mentioned, ICP0/bICP0
can prevent the induction of IFN by sequestering or degrading IRF-3 and IRF-7 (Lin,
Noyce, Collins, Everett, & Mossman, 2004; Melroe, Silva, Schaffer, & Knipe, 2007;
Saira et al., 2007, 2009). ICP0/bICP0 have also been demonstrated to cause both the
activation of NF-κB and the transcription of NF-κB-responsive genes (Diao, Zhang, et
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al., 2005). Furthermore, the ICP0 promoter has previously been shown to contain a NFκB promoter region (Rong et al., 1992), thereby suggesting ICP0 may cause the
activation of NF-κB to increase transcription of its own promoter. VHS is carried in the
tegument of the virion and at the initial stages of infection, it causes the degradation of all
mRNAs present in the cell, effectively shutting-off protein synthesis, including factors
involved in immune response (Hinkley et al., 2000; Koppers-Lalic et al., 2001). Us3 in
HSV-1 infection has been shown to prevent apoptosis by blocking release of cytochrome
c from the mitochondria, thereby preventing one aspect of the anti-viral state (Munger,
Chee, & Roizman, 2001).
2.3.1

PML Bodies
PML bodies have been implicated in the chromatinization, and silencing, of

herpesvirus genomes (Paulus et al., 2010). PML bodies are nuclear bodies involved with
various functions, such as stress response, DNA damage response, apoptosis, and
interferon response. The composition of PML bodies is dynamically regulated by
interferon, as well as various other cytokines, and can differ from PML body to PML
body; yet, there are certain components that are permanently associated with PML
bodies, including the PML protein, Sp100, Daxx, and SUMO (Hagglund & Roizman,
2004; Wang, Long, & Zheng, 2012). During viral infection, PML bodies act as part of the
intrinsic anti-viral response to repress initial viral gene transcription, and as part of the
innate immune response, interferon stimulates increased concentrations of PML, Sp100,
and other PML body constituents to further promote silencing of viral gene transcription.
Point-in-fact, animal experiments have illustrated the proportional relationship between
PML bodies and inhibition of viral replication: mice lacking the PML gene (the main
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constituent of PML bodies) have demonstrated predisposition to viral infections (Bonilla
et al., 2002). Additionally, in the context of α-herpesviral infections, PML bodies have
also been associated with sequestering of viral capsids within PML cages, as well as
transcriptional repression (Wang et al., 2012).
In turn, it is a common viral strategy to affect PML expression or localize to the
PML bodies to affect its architecture (Regad & Chelbi-Alix, 2001). bICP0 is known to
cause the degradation of the PML protein (Gaudreault & Jones, 2011), a trait shared
amongst its homologs in other alphaherpesviruses to varying degrees (Parkinson &
Everett, 2000). Furthermore, studies with HSV-1 have suggested that α-herpesviruses
may even take advantage of this antagonistic relationship between IPC0 and PML bodies
to help regulate the switch between lytic and latent infections. For example, ICP0-null
mutant virus replicates poorly in cell culture; yet when key PML body constituents are
depleted, the same ICP0-null virus exhibits enhanced replication (Roger D Everett et al.,
2006; Wang et al., 2012). On the other side of the coin, bICP0 has been shown to be
expressed as early as 1.5 hours during viral reactivation (Frizzo da Silva, Kook, Doster,
& Jones, 2013), and ICP0 has been demonstrated to be sufficient to relieve transcriptional
repression and reactivate quiescent HSV-1 genomes (Ferenczy, Ranayhossaini, &
Deluca, 2011).
2.3.2

Apoptosis
Apoptosis, or programmed cellular death, can be interferon-induced during viral

infection as a mechanism to prevent further viral replication and spread to neighboring
cells. There are essentially two routes to induce apoptosis: intrinsic and extrinsic.
Intrinsic apoptosis is typically induced by DNA damage, UV radiation, toxins, or
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hypoxia, and leads to the release of cytochrome c from the mitochondria. Cytochrome c
in the cytosol then associates with other proteins to form the apoptosome, which leads to
the cleavage and activation of caspse-3. Extrinsic apoptosis begins with the binding of
tumor necrosis factor (TNF) and similar ligands to death receptors on the cell’s surface,
which leads to the recruitment of other adaptor proteins, ultimately activating caspase-8
followed by caspase-3. Both intrinsic and extrinsic apoptotic signaling pathways
converge at this point, and this is the point of commitment for downstream apoptotic
events and cell death (Benedict, Norris, & Ware, 2002). Viral replication is impeded by
this pro-apoptotic state, and consequently, viruses have evolved different mechanisms to
prevent apoptosis. Such strategies include preventing cytochrome c release and
interfering with TNF receptor signaling, among others (Benedict et al., 2002).
2.4

Ubiquitination during Viral Infection
Ubiquitin is a conserved polypeptide of 76 amino acids that is reversibly bound to

proteins by a covalent bond between its carboxy terminal glycine and a lysine residue on
the target protein. This process is referred to as ubiquitination and occurs in an enzymatic
cascade. Ubiquitin is initially activated in an ATP-dependent manner by the ubiquitinactivating E1 enzyme. As a result, the E1 enzyme forms a thiolester with ubiquitin. The
ubiquitin-polypeptide is then transferred to the ubiquitin-conjugating E2 enzyme via
transthiolation. The final step is the transfer of ubiquitin from the E2-ubiquitin complex
onto the target protein by a ubiquitin-E3 ligase enzyme. Thus, the ubiquitin-E3 ligases
control the specificity of ubiquitination (Hochstrasser, 1996; Komander & Rape, 2012;
Komander, 2009). The most common type of ubiquitin-ligase is the RING (Really
Interesting New Gene) E3 ligase (Deshaies & Joazeiro, 2009; Hochstrasser, 1996). Many
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viruses have a RING ubiquitin-E3 ligase, including K3 and K5 of Kaposi’s Sarcomaassociated Herpesvirus (KSHV) (Coscoy, Sanchez, & Ganem, 2001), M153R of myxoma
virus (Fruh, Bartee, Gouveia, & Mansouri, 2002), and ICP0/bICP0 in HSV-1 and BHV-1,
respectively (Boutell, Sadis, & Everett, 2002; Diao, Qiao, Chen, Wang, & Geng, 2005).
Furthermore, other viral homologs of components of the ubiquitin system have been
found, such as viral ubiquitin and deubiquitinase, indicating that inference with the
ubiquitin system is a common theme during viral infections (Randow & Lehner, 2009).
Ubiquitin can be added to a protein on either a single lysine or onto multiple
lysine residues. Alternatively, polyubiquitin chains can be created by linking ubiquitin
proteins one-by-one onto the growing chain attached to the target protein, or a pre-built
ubiquitin chain can be transferred in its entirety onto the target protein. Furthermore,
since ubiquitin itself has seven lysines, the linkages between chained ubiquitin molecules
can occur in numerous ways. This variety of ubiquitination possibilities determines the
fate and function of the target protein. In the case of ubiquitination by RING E3 ligases,
the type of linkage is determined by the particular E2 enzyme utilized (Deshaies &
Joazeiro, 2009; Metzger, Hristova, & Weissman, 2012).
Classically, ubiquitination is known as a death tag whereas it is associated with
degradation of the modified protein by the 26s proteasome (Wilkinson, 2005). In
particular, addition of a ubiquitin tetramer chained at the Lys-48 residues is recognized
by the 26s proteasome and leads to swift degradation of the tagged protein. However,
while the tagged protein is cleaved into small peptides, the ubiquitin itself is not
degraded, but rather recycled (Komander, 2009). In addition to degradation, ubiquitin
modification can have other effects on the fate of the tagged protein. For example,
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monoubiquitination can serve as a sorting signal in the endocytic pathway, and
polyubiquitination through Lys-63 linkage is required for DNA damage repair
mechanisms (Schnell & Hicke, 2003).
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CHAPTER III
MATERIALS AND METHODS

3.1

Cell Line
CRIB-1 cells (ATCC CRL-11883) were grown in Dulbecco’s modified Eagle’s

medium (HyClone DMEM/High Glucose, Thermo Scientific SH30022.01) supplemented
with 5% (v/v) fetal calf serum, 100 μg/mL streptomycin and 100 U/mL penicillin
(hereafter referred to as complete media), and incubated at 37°C with 5% CO2.
3.2

Virus Strain
The Bovine Herpesvirus-1 Cooper strain (ATCC VR864) was used for all

infections. For infection, cells were rinsed with PBS and inoculated with serum-free
media supplemented antibiotics and containing a specific amount of virus. One hour at
37°C was allowed for virus adsorption, unless otherwise specified; then cells were rinsed
with PBS and overlaid with fresh complete media.
3.3

Plaque Assay/Viral Titration
A six-well plate was seeded with 5x105 cells/well a day prior to the plaque assay.

For the assay, an aliquot of the viral sample was serially diluted in serum-free media10fold; 1 mL of each dilution was used to inoculate a specific well for 1 hour at 37°C.
Wells were then rinsed with PBS and overlaid with a mixture of 5% FBS-media and
0.5% agarose. Plates sat at room temperature for 10 minutes to allow for solidification of
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agarose overlay, then were transferred to the incubator. Upon development of clear
plaques (about 48 to 72 hours post-infection, hpi), the titration was stopped by the
addition of 2% paraformaldehyde supplemented with crystal violet. After sufficient time
for dye absorption, the agarose overlay was rinsed off and plates were air dried overnight.
Viral titer was determined by averaging the number of plaques in each well, taking into
account the specific dilution factor.
3.4

One-Step Growth Curve and bICP0 Expression
Cells were infected with a multiplicity of infection (moi) of 1 and synchronized

for 1 hour at 4°C, after which virus inoculum was removed and replaced with fresh
complete media and the infection preceded as usual. Supernatant and cells were collected
at specific time points. The supernatants were titrated via plaque assay; bICP0 expression
levels were monitored via western blotting of the collected cellular material.
3.5

Western Blotting
Samples were suspended in 2x Laemmli sample buffer (65.8 mM Tris pH 6.8,

2.1% SDS, 26.3% (w/v) glycerol, 0.01% bromophenol blue, 5% β-mercaptoethanol) and
boiled 5 minutes. After a brief spin to pellet any debris, the supernatant was loaded onto a
polyacrylamide gel for SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins
were transferred from gel onto a polyvinylidene fluoride membrane via wet
electroblotting at 200 mAmps for 1 hour, after which, membranes were blocked for 1
hour in 5% non-fat dry milk (NFDM) in TBS-T (50 mM Tris pH 7.4, 150 mM NaCl,
0.05% Tween-20). Unless otherwise noted, primary antibodies were diluted in 5%
NFDM in TBS-T and incubated overnight at 4°C or for 1 hour at room temperature.
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Membranes were washed thrice with TBS-T at 10-minute intervals before incubating
with a secondary antibody conjugated with horseradish peroxidase for 1 hour at room
temperature. Then, membranes were again washed thrice with TBS-T before substrate
(SuperSignal West Pic Chemiluminescent Substrate, ThermoScientific 34080) was added
and bands visualized via chemiluminescence.
3.6

Co-Immunoprecipitation of bICP0
Cells were infected with a moi of 1 and collected at 24 hpi. Uninfected cells were

harvested as a mock-control. Cells were pelleted by centrifugation at 3000 rpm for 5
minutes, and they were washed twice with PBS. Pellets were resuspended in lysis buffer
(50 mM Tris pH 8.0, 150 mM NaCl, 0.5% IGEPAL, 1 mM PMSF, supplemented with
cOmplete™, Mini, EDTA-free protease inhibitor cocktail, Roche 11836170001) for 30
minutes on ice and spun down for 15 minutes at 4000 rpm. The supernatant was
collected, protein concentration was measured by Bradford assay (Biorad 500-0006).
Equivalent amounts of lysates were pre-cleared for 1 hour at 4°C with 0.25 μg of naïve
rabbit IgG (Santa Cruz Biotech sc-2027) and 20 μL of PureProteome™ Protein A
Magnetic Beads (Millipore LSKMAGA10) per 1 mg of lysate protein. Supernatant was
collected, and an aliquot was taken for input control. The pre-cleared lysates were
incubated overnight at 4°C with 4 μg of antibody per 1 mg of protein in each sample:
anti-bICP0 rabbit IgG for infected sample and the mock-control sample and naïve rabbit
IgG for the infected-control sample. Samples were then incubated for 4 hours at 4°C with
Protein A Magnetic Beads, at a ratio of 10 μL of beads per 1 μg of antibody. Supernatant
was collected, and beads were washed thrice with lysis buffer. After the third wash, beads
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were resuspended in 2x Laemmli sample buffer and boiled for 5 minutes.
Immunoprecipitation of bICP0 was verified via western blotting.
3.7

In-Gel Digestion
To prepare co-immunoprecipitated samples for MS analysis, samples were run

through a 10% SDS-PAGE gel, briefly silver stained (Silver Stain Plus, BioRad 1610449) and each lane was cut in a grid-like manner. Gel pieces were washed twice
overnight in wash solution (50% methanol/5% acetic acid). Wash solution was
completely removed and gel pieces were dehydrated with 100% acetonitrile. Gel pieces
were then reduced at room temperature with 10 mM DTT/100 mM ammonium
bicarbonate for 30 minutes and alkylated with 50 mM iodoacetamide for another 30
minutes at room temperature. Samples were dehydrated with 100% acetonitrile,
rehydrated with 100 mM ammonium bicarbonate for 10 minutes, and dehydrated again
with acetonitrile. Proteins in the gel pieces were then digested with sequencing grade
modified trypsin (20 μg of trypsin (Promega V511A) resuspended in 1 mL 50 mM
ammonium bicarbonate) overnight at 37°C. Gel pieces were then incubated with 50 mM
ammonium bicarbonate for 10 minutes and supernatant was collected. Gel pieces were
then twice incubated 10 minutes with extraction buffer (50% acetonitrile, 5% formic
acid) and supernatant was added to the collection tube. Finally, samples were dried by
vacuum centrifugation, resuspended in 20 μL of buffer A (2% acetonitrile, 0.1% formic
acid), and transferred to liquid chromatography (LC) vials.
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3.8

Cleaning Samples before LC
To ensure no gel pieces enter the LC column, samples for the second co-IP were

cleaned with C18 ZipTips (Millepore ZTC18S096). First, the zip tip was wetted with
acetonitrile twice, then equilibrated twice with 0.1% formic acid. Peptides were then
bound to the packing by repeated aspiration of the sample and washed twice with 0.1%
formic acid. Peptides were eluted using 70% acetonitrile into a fresh tube and again dried
by vacuum centrifugation before resuspended in 20 μL of buffer A and transferred to a
LC vial.
3.9

Proteomic Analysis
The peptides were analyzed by liquid chromatography tandem mass spectrometry

(LC-MS/MS) by using LTQ Velos (Thermo). For in-line chromatography, we used 75
μm i.d. x 15 cm reverse phase C18 column (Thermo), which was controlled by an
Ultimate 3000 nanoflow HPLC (Dionex). Peptides were eluted using an acetonitrile
gradient of 0.2%-55% solvent B (99.9% acetonitrile, 0.1% formic acid) at a flow rate of
0.3 μL/min, and were then introduced into an LTQ Velos mass spectrometer (Thermo
Fisher), which was operated in the LTQ data-dependent mode, automatically switching
between MS and MS/MS. Full scan MS spectra (300-2,000 amu) were analyzed in a
profile mode by the LTQ analyzer and the most intense ions were selected for collisioninduced fragmentation (CID) in the LTQ at normalized collision energy of 35% and
activation time of 40 ms.
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3.10 Database Searching
Tandem mass spectra were extracted by Proteome Discoverer version 1.4.0.288.
All MS/MS samples were analyzed using Sequest (Thermo Fisher Scientific, San Jose,
CA, USA; version 1.4.0.288) and X! Tandem (The GPM, thegpm.org; version CYCLONE
(2010.12.01.1)). Sequest was set up to search a subset of the NCBI-GenBank database
(http://www.ncbi.nlm.nih.gov/genbank; Benson, Karsch-Mizrachi, Lipman, Ostell, &
Wheeler, 2005) comprised of the bovine and BHV-1 proteome (26752 entries), assuming
tryptic digestion. X! Tandem was set up to search a subset of the above-mentioned
database, also assuming the presence of tryptic digests. Sequest and X! Tandem were
searched with a fragment ion mass tolerance of 0.80 Da and a parent ion tolerance of 2.0
Da. Glu->pyro-Glu of the n-terminus, ammonia-loss of the n-terminus, gln->pyro-Glu of
the n-terminus, oxidation of methionine and carbamidomethyl of cysteine were specified
in X! Tandem as variable modifications. Oxidation of methionine and carbamidomethyl
of cysteine were specified in Sequest as variable modifications.
3.11 Criteria for Protein Identification
Scaffold (version Scaffold_4.2.0, Proteome Software Inc., Portland, OR) was
used to validate MS/MS-based peptide and protein identifications. Peptide identifications
were accepted if they could be established at greater than 22.0% probability to achieve a
false discovery rate (FDR) less than 2.0%. Peptide Probabilities from Sequest were
assigned by the Scaffold Local FDR algorithm. Peptide Probabilities from X! Tandem
were assigned by the Peptide Prophet algorithm (Keller, Nesvizhskii, Kolker, &
Aebersold, 2002) with Scaffold delta-mass correction. Protein identifications were
accepted if they could be established at greater than 95.0% probability and contained at
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least 2 identified peptides. Protein probabilities were assigned by the Protein Prophet
algorithm (Nesvizhskii, Keller, Kolker, & Aebersold, 2003). Proteins that contained
similar peptides, and could not be differentiated based on MS/MS analysis alone, were
grouped to satisfy the principles of parsimony.
3.12 Computational Analysis of bICP0 PPI Profile
The MS-derived list of protein interactors was computationally analyzed to
highlight any common conserved protein domains, biological functions, and pathways. A
batch Conserved Domain Search (CD-Search) of the interactors in the Conserved
Domain Database (CDD) offered by NCBI was performed (Marchler-Bauer & Bryant,
2004). Biological functions of each interactor was analyzed based on gene ontology (GO)
annotation as obtained by GORetriever and GOSlimViewer available from AgBase
(McCarthy et al., 2006). Pathway and network analysis were generated through the use of
QIAGEN’s Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City,
www.qiagen.com/ingenuity) and STRING (Search Tool for the Retrieval of Interacting
Genes/Proteins, (Jensen et al., 2009)).
3.13 Confocal Microscopy
Cells were seeded at 7x104 cells/well onto a 4-well Millicell EZ slide (Millipore
PEZGS0416) and infected the next day at either a moi of 2 or 4 for 8 or 17 hours. Cells
were fixed in ice-cold ethanol for 5 minutes at -20°C. The slide was then washed twice at
5-minute intervals in PBS, and blocked for 1 hour with 3% bovine serum albumin (BSA)
in PBS. Next, the slide was incubated for 1.5 hours at room temperature with a solution
of 1:50 diluted primary antibody in TBS-T with 1% BSA, and then washed thrice in
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TBS-T for 10 minutes each. In the dark, the slide was then incubated with the secondary
antibody conjugated to AlexaFluor488 (anti-goat) (Jackson ImmunoResearch #705-546147) or AlexaFluor647 (anti-rabbit) (Jackson ImmunoResearch #711-606-152)
fluorochromes diluted 1:50 in TBS-T with 1% BSA for 1 hour at room temperature.
Again, the slide was washed thrice in TBS-T, followed by application of mounting
medium containing DAPI (Fluoroshield, Sigma F6057-20ML), and a coverslip was
placed on top. Once the mounting medium gelled, slides were stored at 4°C in the dark.
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CHAPTER IV
RESULTS

4.1

bICP0 Expression
In order to be sure of pulling down as many interactors as possible, we first

determined the time of bICP0 maximal expression. For this, cells were synchronously
infected at a moi of 1 and collected throughout a 24-hour time period. bICP0 expression
at each collected time point was monitored via western blot (Figure 4.1). bICP0 was
observed as early as 3 hpi and expression levels were observed to continuously increase
and peak at 24 hpi. As expected, there was no bICP0 expression in uninfected cells. Actin
was used as a loading control. The observed early expression of bICP0 corresponds with
the induction of its immediate-early promoter, driving bICP0 expression before release of
new virions (Figure 4.2). We decided to use samples at 24 hpi for the co-IP due to both
the convenience in collection and high expression of bICP0. Furthermore, for the material
used for the co-IP, cells were not synchronized in an attempt to capture bICP0
interactions at various stages of infection within individual cells.
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Figure 4.1

bICP0 Expression during Infection of CRIB-1 Cells

CRIB-1 cells were inoculated with BHV-1 at a moi of 1 and collected at the indicated
times post infection (hpi). Uninfected cells were used as a mock control and,
consequently, could not express the viral protein. Actin was used as a loading control.

Figure 4.2

One-Step Growth Curve for BHV-1 in CRIB-1 Cell Culture

CRIB-1 cells were inoculated with BHV-1 at a moi of 1 and synchronized at 4°C for 1
hour before returning them to incubate at 37°C with 5% CO2. Supernatant from infected
samples was collected at the indicated time points and titrated to determine viral
concentration in plaque-forming units (PFU) per milliliter.
4.2

bICP0 co-Immunoprecipitation (co-IP)
In order to immunoprecipitate bICP0, we used a polyclonal antibody against two

immunogenic regions of bICP0. Cells were infected with BHV-1 at a moi of 1, collected
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at 24 hpi, and split into two samples. Mock-infected cells were also harvested to serve as
one of the controls. The two controls were designed to identify any cellular and viral nonspecific interactions with the anti-bICP0 antibody (Table 4.1). The mock control
consisted of uninfected cell lysates and the bICP0-specific antibody was used for the IP.
A second control consisted of infected cell lysates (the same infected cells as the bICP0
co-IP) and naïve rabbit IgG was used for the IP (same species as the α-bICP0 antibody).
The object was to control for non-specific protein interactors as might happen with the
bICP0 co-IP.
Table 4.1

Design of the bICP0 co-IP and Control IPs
Sample
bICP0 co-IP
Mock Control
Infected Control

Cell Lysate
Infected
Mock Infected
Infected

Antibody for IP
α-bICP0
α-bICP0
naïve rabbit IgG

Cells were lysed, clarified, and pre-cleared with naïve rabbit IgG and protein A
beads. Pre-cleared lysates were then incubated overnight with either anti-bICP0 or naïve
IgG, according to Table 4.1. Samples were then separated on a 10% SDS-polyacrylamide
gel, and proteins were transferred to a PVDF membrane for bICP0 detection via western
blotting. In Figure 4.3, lanes 4, 6, and 8 are the proteins immunoprecipitated with the
indicated antibody, while lanes 3, 5, and 7 represent the fraction of proteins not pulled
down by the antibody-bead mixture (left in the supernatant, SN). Lanes 1 and 2 are the
input controls, and as expected, bICP0 is only seen in the infected lysate. bICP0 was only
detected when the anti-bICP0 antibody (lane 4) was used and was not
immunoprecipitated by any of the two controls (lanes 6 and 8). In addition, bICP0
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remained in the unbound fraction (or SN) in the infected control (lane 7), further
supporting the specificity of the pull-down.

Figure 4.3

bICP0 Immunoprecipitation

A and B are from the same membrane; B same as A, longer exposure. Samples of the
mock and infected input material are in lanes 1 and 2, respectively. Immunoprecipitated
proteins are in lanes 4, 6, and 8. Proteins that did not interact with the indicated antibody
are in lanes 3, 5, and 7.
Two issues complicated first attempts at bICP0 immunoprecipitation. In the
beginning, bICP0 was not being pulled down. Altering the composition of the lysis buffer
had no effect, but amending the immunoprecipitation protocol to include a pre-clearing
step with naïve rabbit IgG, in addition to the Protein A beads, resolved this issue. Another
complication was the presence of a nonspecific band that appeared in the IP sample and
two controls. This band has nearly the same molecular weight of bICP0, so the success of
these early IPs could not be determined. However, upon greater separation on the gel via
increased percentage of polyacrylamide and run-time, bICP0 could be distinguished from
this nonspecific band, as seen in Figure 4.3.
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Once bICP0 could be reliably immunoprecipitated, a large-scale co-IP with 20 mg
of whole cell lysate input (per sample) was performed. An aliquot of each sample was
tested to verify the successful pull-down of bICP0. The samples were then run on a large
10% SDS-polyacrylamide gel until the dye front was almost run off the gel. The gel was
briefly silver stained to identify the heavy chain of the antibody used in the IP (~55 kD),
the thick heavy chain band was used as a visual reference and was easily excised and not
included in further MS procedures. Individual lanes were sliced and diced in a grid-like
manner to generate 109 bands for in-gel digestion and subsequent LC-MS/MS analysis
(Figure 4.4). An identical second large-scale co-IP was performed and the samples were
run on a 10% SDS-polyacrylamide mini-gel. A mini-gel was used for the second co-IP to
reduce the number of samples (and processing time) for the in-gel digestion later.
However, both gels were processed in exactly the same manner.
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Figure 4.4

Diagram of Sample Processing from Gel to Protein Identification

Samples were first run on a 10% polyacrylamide gel and briefly silver-stained. Individual
lanes were sliced and diced for in-gel trypsin digestion. The resulting peptides were
analyzed by LC-MS/MS and spectra were run against a database of the bovine and BHV1 proteomes.
4.3

Curation of bICP0 Experimental Protein-Protein Interaction (PPI) Profile
The MS data generated from both co-IP experiments was pooled and sieved to

generate a PPI profile of 98 cellular and 15 viral proteins (Tables 4.2 & 4.3). The data
was filtered with a 2% false discovery rate (FDR) threshold for peptide identification,
requiring a minimum of 2 peptides, and 95% confidence for protein identity. The
quantitative variance test offered by the Scaffold software was used to identify proteins
that had significantly higher spectra hits in one sample versus the two other samples.
However, since this test also identified non-specific interactors that had more spectra hits
in the control IPs, the dataset was then manually curated to exclude proteins significantly
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pulled down in the control samples and only keep those proteins overrepresented in the
bICP0 IP sample. This was done individually to both co-IP datasets. These datasets were
then compared to determine if any of the significant hits in one experiment were
counteracted in the other co-IP (i.e., while appearing as overrepresented in the bICP0 IP
of the first co-IP, the same protein may have been rejected in the second co-IP due to a
significant presence in one of the control samples); those proteins were also excluded.
The final curated list can be seen in Tables 4.2 and 4.3, representing the cellular and viral
protein interactors, respectively.
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Table 4.2

Cellular Proteins in the bICP0 Experimental PPI Profile
Accession Number2

Molecular
Weight

Sequence
Coverage

Spectra Hits
bICP0 co-IP

Spectra Hits
Mock Control

Spectra Hits
Infected Control

329664922
134085695
118150814
358414113
27806769
77736103
122692549
300794966
125630649
297481071
297482744

76 kDa
57 kDa
136 kDa
418 kDa
85 kDa
35 kDa
28 kDa
146 kDa
89 kDa
38 kDa
418 kDa

5%
6%
3%
2%
6%
7%
11%
4%
3%
7%
1%

83
15
9
8
8
4
4
4
3
2
2

0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0

114051487
27806559
77736203
27806929
115496448
116004359

12 kDa
37 kDa
36 kDa
26 kDa
26 kDa
43 kDa

10%
9%
6%
11%
6%
5%

42
10
6
4
2
2

0
0
0
0
0
0

0
5
0
0
0
0

194685481
297474462
297474454 (+1)
359072156
84000361
62751593
119901005
62988288
115496946
297481169

59 kDa
64 kDa
68 kDa
527 kDa
58 kDa
15 kDa
269 kDa
58 kDa
97 kDa
154 kDa

14%
10%
5%
1%
4%
19%
2%
5%
3%
2%

138
85
22
9
6
3
2
2
2
2

21
0
0
0
0
0
0
0
0
0

28
39
0
0
3
0
0
0
0
0

CYTOPLASM
Glyceraldehyde-3-Phosphate Dehydrogenase, Testis-Specific
PREDICTED: Protein Shroom2, Partial
Fibronectin Type III Domain-Containing Protein 3B
PREDICTED: Vomeronasal Type-1 Receptor 4
Mevalonate Kinase
Elongation Factor 1-Delta
AP-3 Complex Subunit Sigma-1
Ras-Related Protein Rab-1B
Phospholipase D3
PREDICTED: Cytoskeleton-Associated Protein 4 Isoform 1
Protein Disulfide-Isomerase A5 Precursor
PREDICTED: Uncharacterized Protein LOC616065
Inositol 1,4,5-Trisphosphate Receptor Type 2

110626121
119919571
329664282
359075969
62751666
331028779
114053131
115495993
118151178
359065674
114052625
297484146
27805961

43 kDa
148 kDa
133 kDa
56 kDa
42 kDa
31 kDa
22 kDa
22 kDa
55 kDa
80 kDa
60 kDa
15 kDa
308 kDa

10%
2%
3%
6%
6%
13%
7%
11%
8%
4%
4%
19%
1%

8
7
7
7
6
4
3
3
3
3
3
3
2

0
0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0

NUCLEUS & CYTOPLASM
Eukaryotic Translation Initiation Factor 2 Subunit 1
SH3 Domain-Binding Glutamic Acid-Rich-Like Protein 3
Stress-Induced-Phosphoprotein 1
Nucleolysin TIAR
DNA-(Apurinic Or Apyrimidinic Site) Lyase
PREDICTED: RNA-Binding Protein 25

28461253
77736471
78369310
300796220
223278400
359069757

36 kDa
10 kDa
62 kDa
42 kDa
36 kDa
100 kDa

13%
19%
4%
7%
8%
4%

12
9
6
6
4
2

0
4
0
0
0
0

0
0
0
0
0
0

PLASMA MEMBRANE & EXTRACELLULAR
Kappa-Casein Precursor
Voltage-Dependent N-Type Calcium Channel Subunit Alpha-1B
14-3-3 Protein Epsilon
PREDICTED: Collagen Alpha-3(VI) Chain Isoform 1
Integrin Beta-1 Precursor
Sodium/Potassium-Transporting ATPase Subunit Alpha-1
PREDICTED: LOW QUALITY PROTEIN: Collagen Alpha-4(IV) Chain, Partial
Retinal-Specific ATP-Binding Cassette Transporter
Alpha-Enolase
Protocadherin Gamma Subfamily C, 3 Isoform 1
A Disintegrin and Metalloproteinase with Thrombospondin Motifs 4 Precursor
Collagen Alpha-2(XI) Chain Precursor
PREDICTED: Multimerin-2
PREDICTED: Complement C4-A

27881412
27807135
27806197
297473446
27805959
116003819
358422144
27806343
87196501
166159170
31982399
114051163
297491573
358420619

21 kDa
261 kDa
29 kDa
342 kDa
88 kDa
113 kDa
49 kDa
257 kDa
47 kDa
101 kDa
90 kDa
172 kDa
104 kDa
193 kDa

11%
1%
20%
1%
2%
3%
3%
1%
6%
5%
4%
3%
3%
2%

26
10
8
6
6
3
3
2
2
2
2
2
2
2

12
0
0
0
0
0
0
0
0
0
0
0
0
0

0
0
4
0
0
0
0
0
0
0
0
0
0
0

262118301
329663351
330688463
94966849
284813533
300794828
32880219
297487980
330864791
297485192
329664954
331028504
60302887
157073980
297473671
297486577
329664158
358421313
359070056
297490134
297476722
331284182
358416277
359069518
358417794 (+1)
27807043
114051401
134085918
297471497
297471727
297477228
300795791
300796567
300797657
329664794
359075813
297488054 (+1)
358417560 (+1)

52 kDa
119 kDa
281 kDa
31 kDa
100 kDa
220 kDa
54 kDa
189 kDa
34 kDa
359 kDa
38 kDa
197 kDa
36 kDa
54 kDa
18 kDa
24 kDa
270 kDa
320 kDa
222 kDa
108 kDa
76 kDa
307 kDa
445 kDa
250 kDa
295 kDa
229 kDa
66 kDa
66 kDa
86 kDa
773 kDa
44 kDa
59 kDa
87 kDa
135 kDa
91 kDa
61 kDa
51 kDa
59 kDa

27%
5%
3%
15%, 13%
4%
1%
7%
2%
8%
2%
10%
3%
6%
5%
11%
11%
2%
2%
1%
2%
5%
1%
1%
2%
1%
2%
5%
5%
5%
0%
9%
8%
5%
2%
5%
6%
10%
5%

101
14
12
11, 13
8
7
6
6
6
5
5
5
4
4
4
4
4
4
4
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2

5
0
0
0, 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

11
0
0
0, 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Protein Name1
NUCLEUS
Splicing Factor, Proline- And Glutamine-Rich
E3 SUMO-Protein Ligase PIAS4
Splicing Factor 3B Subunit 3
PREDICTED: Spectrin Beta Chain, Brain 4-Like
Aconitate Hydratase, Mitochondrial Precursor
Leucine-Rich Repeat-Containing Protein 59
Splicing Factor U2AF 35 kDa Subunit
Splicing Factor 3B Subunit 1
Splicing Factor 3A Subunit 1
PREDICTED: Regulatory Factor X-Associated Protein
PREDICTED: Histone-Lysine N-Methyltransferase MLL, Partial
MITOCHONDRIA
Cytochrome C
L-Lactate Dehydrogenase A Chain
Malate Dehydrogenase, Cytoplasmic
Adenylate Kinase 2, Mitochondrial
Dihydropteridine Reductase
Pyruvate Dehydrogenase E1 Component Subunit Alpha, Testis-Specific Form, Mitochondrial
CYTOSKELETON
PREDICTED: Keratin, Type I Cytoskeletal 10-like Isoform 2
PREDICTED: Keratin, Type II Cytoskeletal 2 Epidermal
PREDICTED: Keratin, Type II Cytoskeletal 2 Oral
PREDICTED: Plectin-like
T-Complex Protein 1 Subunit Delta
Profilin-1
PREDICTED: Centriolin
Brain-Specific Angiogenesis Inhibitor 1-Associated Protein 2
Heat Shock Protein 105 kDa
PREDICTED: Centromere Protein J

1

UNCATEGORIZED
**Keratin, Type I Cytoskeletal 14
Leucine Zipper Protein 1
Filamin-A
*Heterogeneous Nuclear Ribonucleoprotein A/B
26S Proteasome Non-ATPase Regulatory Subunit 2
Zinc Finger Protein 638
E3 Ubiquitin-Protein Ligase TRIM21
PREDICTED: IQ Motif Containing GTPase Activating Protein 1
**Heterogeneous Nuclear Ribonucleoprotein H3
PREDICTED: Zinc Finger Protein 469
Short Stature Homeobox Protein 2
**Nestin
Aldose Reductase
GRAM Domain-Containing Protein 1C
PREDICTED: Peptidyl-Prolyl Cis-Trans Isomerase A
PREDICTED: Class A Basic Helix-Loop-Helix Protein 9
Talin-1
PREDICTED: Immunoglobulin-like and Fibronectin Type III Domain-Containing Protein 1-like
PREDICTED: HEAT Repeat-Containing Protein 5B Isoform 2
PREDICTED: Xylosyltransferase 1
PREDICTED: PML-RARA-Regulated Adapter Molecule 1
Protein PRRC2C
PREDICTED: Uncharacterized Protein KIAA1109, Partial
PREDICTED: Ninein Isoform 2
PREDICTED: PDZ Domain-Containing Protein 2
Phosphatidylinositol 4-Kinase Alpha
Putative Phospholipase B-like 2 Precursor
GTP-Binding Protein 2
PREDICTED: Protein FAM123C
PREDICTED: Nebulin
PREDICTED: Thioredoxin Domain-Containing Protein 15
BEN Domain-Containing Protein 4
Myotubularin-Related Protein 10
Protein Diaphanous Homolog 3
Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2
PREDICTED: LOW QUALITY PROTEIN: PNMA-Like 2
PREDICTED: SH2 Domain-Containing Protein 7
PREDICTED: Forkhead Box Protein K2, Partial

Protein names are as listed in the database used for MS identification.
Accession numbers refer to the NCBI GI number of a specific version of a database
entry. *Indicates protein pulled down in both co-IP experiments.
**Indicates protein pulled down in both co-IP experiments, but was only considered
significant in one of the co-IPs. Entries with no asterisk are proteins that only appeared in
one experiment.
2

Note: Subcellular locations listed for each protein are as noted in the retrieved GO
annotations. Proteins are listed in descending order of number of peptides (spectra hits).
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Table 4.3

Viral Proteins in the bICP0 Experimental PPI Profile
Spectra
Spectra
Spectra
Sequence
Hits
Hits
Hits Mock
Coverage bICP0 coInfected
Control
IP
Control

Process

Accession
Number2

Molecular
Weight

*Ubiquitin E3 Ligase ICP0
(bICP0)

Regulation
Of Transcription,
DNA-Templated

9629879

68 kDa

10.50%,
9.00%

47, 41

0, 0

0, 0

*Tegument Protein VP13/14
(VP8)

Regulation
Of Transcription,
DNA-Templated

9629828

81 kDa

9.20%, 3.70%

40, 2

0, 0

6, 0

*DNA Polymerase
Processivity Subunit

DNA Replication

9629832

43 kDa

16.70%,
5.90%

18, 4

0, 0

5, 0

*Envelope Glycoprotein C
(gC)

Viral Process

9629830

54 kDa

15, 17

0, 0

0, 0

*Virion Protein V67

Viral Process

9629882

27 kDa

11, 7

0, 0

0, 0

Viral Process

9629888

61 kDa

6.26%, 3.80%

11, 2

0, 0

0, 0

Regulation
Of Transcription,
DNA-Templated

155041720

51 kDa

5.00%

10

0

0

Nucleic Acid
Phosphodiester Bond
Hydrolysis

9629833

50 kDa

4.14%

8

0

0

Ribonucleotide Reductase
Subunit 2

DNA Replication

9629834

35 kDa

7.64%

6

0

0

DNA Packaging Tegument
Protein UL17

Virion Maturation

9629859

73 kDa

6.00%

5

0

0

Ribonucleotide Reductase
Subunit 1

DNA Replication

9629835

86 kDa

1.91%

3

0

0

9629886

45 kDa

9.40%, 6.47%

3, 11

0, 0

0, 0

9629836

50 kDa

6.12%

3

0

0

9629874

34 kDa

4.65%

2

0

0

9629884

50 kDa

5.13%

2

0

0

Protein Name1

*Envelope Glycoprotein E
(gE)
Transactivating Tegument
Protein VP16
(VP16)
Tegument Host Shutoff
Protein
(VHS)

*Envelope Glycoprotein D
Viral Entry Into Host
(gD)
Cell
**Capsid Triplex Subunit 1
Virion Maturation
()
Uracil DNA Glycosylase
DNA Repair
()
Serine/Threonine Protein
Kinase US3
Protein Phosphorylation
(Us3)
1

14.40%,
10.00%
16.00%,
11.90%

Protein names are as listed in the database used for MS identification.
Accession numbers refer to the NCBI GI number of a specific version of a database
entry. *Indicates protein pulled down in both co-IP experiments.
**Indicates protein pulled down in both co-IP experiments, but was only considered
significant in one of the co-IPs. Entries with no asterisk are proteins that only appeared in
one experiment.
2

Note: Processes listed for each protein are as noted in the retrieved GO annotations.
Proteins are listed in descending order of number of peptides (spectra hits).
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4.4

Protein Interactors of Note
The protein interactors of bICP0 are functionally classified in a later chapter.

Some interactors are in line with known functions of bICP0. However, certain interactors
involved in mRNA processing or in the intrinsic apoptosis signaling caught our attention.
These putative interactions are novel to published reports on bICP0 and its homologs, and
such associations could expand bICP0’s functionality in avenues previously unknown.
We tested for co-localization with bICP0 via confocal microscopy. Of the splicing
factors, we focused on heterogeneous nuclear ribonucleoproteins A/B and H3 (hnRNP
A/B & H3) and splicing factor, proline- and glutamine-rich (SFPQ).
In the infected cell, bICP0 is predominately found in the nucleus, forming a
characteristic, punctate pattern in confocal or fluorescent micrographs (Figure 4.5).
Confocal microscopy of both bICP0 and hnRNP A/B showed a distinct redistribution of
hnRNP A/B in infected cells (Figure 4.6). As can be seen in Figure 4.6, mock-infected
cells exhibit a clear exclusion of hnRNP A/B from the nucleus, except for a single speck
in the nucleus. However, in the infected cell (indicated by the presence of bICP0), there
appears to be an influx of hnRNP A/B into the nucleus. Moreover, the two seem to colocalize, as is suggested by the yellow color on the signal overlay panel. A similar
examination of the cellular distribution of hnRNP H3 was attempted, however the
primary antibody proved to be nonreactive for bovine hnRNP H3 (data not shown).
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Figure 4.5

Confocal Microscopy Image of bICP0 Distribution in BHV-1 Infected
Cells

Cells were infected with a moi of 0.75, then fixed at 17 hpi. α-bICP0 was detected with
AlexaFluor 647-conjugated α-rabbit donkey IgG fragment. Nuclei were stained with
DAPI. Magnification is 400X, then digitally zoomed in for better visualization of detail.

Figure 4.6

Confocal Microscopy Image of bICP0 and hnRNP A/B Distribution in
Mock and BHV-1 Infected Cells

Cells were infected with a moi of 2, then fixed at 8 hpi. α-bICP0 was detected with
AlexaFluor 647-conjugated α-rabbit donkey IgG fragment. α-hnRNP A/B was detected
with AlexaFluor 488-conjugated α-goat donkey IgG fragment. Nuclei were stained with
DAPI. Magnification of first two rows is 400X. White box indicates area selected for
enlargement, below. Outlined arrow indicates an uninfected cell, filled arrow indicates an
infected cell.
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The third splicing factor, SFPQ was noted to be present at higher concentrations
in infected cell lysate, as seen by western blotting (Figure 4.7). Confocal microscopy
revealed co-localization of SFPQ and bICP0 in the nucleus, indicated by a yellow-orange
color in the indicated infected cells (Figure 4.8).

Figure 4.7

Increased SFPQ Expression in BHV-1 Infected Cells

Cells were infected with a moi of 1 and collected at 21 hpi. Uninfected cells were also
harvested for the purpose of comparison. Actin was used as a loading control.

Figure 4.8

Confocal Microscopy Image of bICP0 and SFPQ Distribution in Mock and
BHV-1 Infected Cells

Cells were infected with a moi of 2, then fixed at 8 hpi. α-bICP0 was detected with
AlexaFluor 647-conjugated α-rabbit donkey IgG fragment. α-SFPQ was detected with
AlexaFluor 488-conjugated α-mouse goat IgG fragment. Nuclei were stained with DAPI.
Magnification of first two rows is 400X. White box indicates area selected for
enlargement, below. Outlined arrow indicates an uninfected cell, filled arrow indicates an
infected cell.
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In addition to the afore mentioned splicing factors, the cellular distribution and
possible co-localization with bICP0 of cytochrome c, a factor involved in the intrinsic
apoptosis signaling pathway, was also examined via confocal microscopy. Cytochrome c
is normally localized in the mitochondria of a healthy cell, but as a reaction to cellular
stress (such as induced by a viral infection), cytochrome c can exit the mitochondria and
induce a chain reaction of apoptotic signaling events in the cytosol. As is seen in the top
panel of Figure 4.7, cytochrome c is mostly expressed in the cytoplasm, and we could
observe a fine punctate pattern in the cytoplasm that is excluded from the nucleus. During
apoptosis, cytochrome c is released from the mitochondria and disseminates throughout
the cell evenly. We show this effect with a drug, zearaleone, which promotes cytochrome
c release from the mitochondria. As can be seen in the presence of zearalenone,
cytochrome c is distributed evenly in the nucleus and cytoplasm (Figure 4.7, middle
panel). BHV-1 infection induces a similar dissemination of cytochrome c, as seen in the
infected cell in the bottom panel of Figure 4.7. Furthermore, dissemination of cytochrome
c into the nucleus appears most concentrated in the vicinity of bICP0, even if we did not
observe co-localization of the two proteins.
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Figure 4.9

Confocal Microscopy Image of bICP0 and Cytochrome C Distribution in
Mock, Zearalenone-Treated Mock, and BHV-1 Infected Cells

Cells were treated with 25 µg/mL of zearalenone and fixed at 20 hours post treatment, or
infected with a moi of 2 and fixed at 8 hpi. α-bICP0 was detected with AlexaFluor 647conjugated α -rabbit donkey IgG fragment. α-cytochrome c was detected with AlexaFluor
488-conjugated α-goat donkey IgG fragment. Nuclei were stained with DAPI.
Magnification of first two rows is 400X. White box indicates area selected for
enlargement, below. Outlined arrow indicates an uninfected cell, filled arrow indicates an
infected cell.
4.5

Final Note on bICP0 PPI Profile
Due to the nature of the co-IP, it is likely that a large portion of the proteins

identified in Tables 4.2 and 4.3 may not directly interact with bICP0, but rather they may
form part of a complex where bICP0’s binding with a single constituent was sufficient to
precipitate the entire complex. Similarly, transient interactions, such as would occur
between ubiquitin E2 and E3 enzymes, are very difficult to detect by co-IP and may not
be represented in the bICP0 PPI profile. Importantly, these experiments entail
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endogenous levels of each protein. Upon overexpression of one or both, the interactions
may be more prominent and detectable.
Furthermore, care was taken in the design of the experiment to prevent
identification of false positives, but it is possible that some nonspecific interactions may
have been included in the finalized bICP0 PPI profile. Measures employed to prevent
false positives were the use of two negative control IPs and pre-clearing of the lysates
with the control antibody (Adams, Zhang, Poustovoitov, Seeholzer, & Ohh, 2005). While
other measures and methods (such as cross-linking with formaldehyde and tandem
affinity purification) could also have been employed, based on the spectra hits recorded
for the bICP0 co-IP versus the two controls (Tables 4.2 and 4.3), we are confident of our
results. As can be seen, most proteins in the PPI profile were only found in the bICP0 coIP sample and did not receive any hits in the two controls.
Finally, while the two co-IPs can be considered biological replicates, for
proteomic analysis this is not the case. The conditions were not completely identical for
each co-IP, they were performed on different days, with different passages of cells, and
the second co-IP underwent an extra cleaning step prior to MS analysis. These slight
variations in handling and processing of samples may explain the few instances of
overlap between the two co-IPs. However, regardless of these variations, each co-IP can
stand on its own merit as a true experimentally-derived PPI profile for bICP0, and the
overlapping proteins serve as further support.
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CHAPTER V
DATA ANALYSIS

5.1

GO Annotation Analysis
To gain insight into biological processes possibly influenced by bICP0 during

infection, GO annotations for each interactor was retrieved and organized using tools
available at AgBase (McCarthy et al., 2006). Several cellular processes important to viral
infection were recognized, including protein modification, transcription, and immune
response (Table 5.1). These processes are related to known functions of bICP0 as an
ubiquitin E3 ligase, as a transcription factor, and as a repressor of interferon induction,
further supporting the putative association between particular interactors and bICP0.
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Table 5.1
Process

Cellular Processes of bICP0 Interactors, As Predicted by GO Annotations
Interactors
14-3-3 Protein Epsilon
AP-3 Complex Subunit Sigma-1
Brain-Specific Angiogenesis Inhibitor 1-Associated Protein 2
Inositol 1,4,5-Trisphosphate Receptor Type 2
Integrin Beta-1 Precursor
Kappa-Casein Precursor
PREDICTED: Centromere Protein J

Protein
Trafficking

26S Proteasome Non-ATPase Regulatory Subunit 2
Alpha-Enolase
DNA-(Apurinic Or Apyrimidinic Site) Lyase

Catabolism

Glyceraldehyde-3-Phosphate Dehydrogenase, Testis-Specific
GTP-Binding Protein 2
L-Lactate Dehydrogenase A Chain

* Interactors
PREDICTED: Histone-Lysine N-Methyltransferase MLL, Partial
PREDICTED: PML-RARA-Regulated Adapter Molecule 1
Profilin-1
Ras-Related Protein Rab-1B
Retinal-Specific ATP-Binding Cassette Transporter
Sodium/Potassium-Transporting ATPase Subunit Alpha-1
Voltage-Dependent N-Type Calcium Channel Subunit Alpha-1B

*

Malate Dehydrogenase, Cytoplasmic
Phospholipase D3
Pyruvate Dehydrogenase E1 Component Subunit Alpha, Testis-Specific Form,
Mitochondrial
Retinal-Specific ATP-Binding Cassette Transporter
Sodium/Potassium-Transporting ATPase Subunit Alpha-1

Protein
Modification

14-3-3 Protein Epsilon
Adenylate Kinase 2
E3 SUMO-Protein Ligase PIAS4
E3 Ubiquitin-Protein Ligase TRIM21
Eukaryotic Translation Initiation Factor 2 Subunit 1
Mevalonate Kinase

Myotubularin-Related Protein 10
Phosphatidylinositol 4-Kinase Alpha
PREDICTED: Histone-Lysine N-Methyltransferase MLL, Partial
PREDICTED: Peptidyl-Prolyl Cis-Trans Isomerase A
Serine/Threonine Protein Kinase Us3

Signal
Transduction

Brain-Specific Angiogenesis Inhibitor 1-Associated Protein 2
E3 SUMO-Protein Ligase PIAS4
Elongation Factor 1-Delta
Inositol 1,4,5-Trisphosphate Receptor Type 2
Integrin Beta-1 Precursor

Phosphatidylinositol 4-Kinase Alpha
PREDICTED: Multimerin-2
PREDICTED: PML-RARA-Regulated Adapter Molecule 1
PREDICTED: Vomeronasal Type-1 Receptor 4
Ras-Related Protein Rab-1B

Transcription

DNA-(Apurinic Or Apyrimidinic Site) Lyase
E3 SUMO-Protein Ligase PIAS4
E3 Ubiquitin-Protein Ligase TRIM21
PREDICTED: Forkhead Box Protein K2, Partial
PREDICTED: Histone-Lysine N-Methyltransferase MLL, Partial

PREDICTED: Regulatory Factor X-Associated Protein
Profilin-1
Splicing Factor, Proline- And Glutamine-Rich
Tegument Protein VP13/14
Transactivating Tegument Protein VP16

Stress Response

DNA-(Apurinic Or Apyrimidinic Site) Lyase
E3 SUMO-Protein Ligase PIAS4
Eukaryotic Translation Initiation Factor 2 Subunit 1
Heat Shock Protein 105 Kda

PREDICTED: Complement C4-A
PREDICTED: Xylosyltransferase 1
Protein Disulfide-Isomerase A5 Precursor
Uracil DNA Glycosylase

DNA Metabolism

DNA Packaging Tegument Protein UL17
* Ribonucleotide Reductase Subunit 1
DNA Polymerase Processivity Subunit
* Ribonucleotide Reductase Subunit 2
DNA-(Apurinic Or Apyrimidinic Site) Lyase
Uracil DNA Glycosylase
PREDICTED: Histone-Lysine N-Methyltransferase MLL, Partial

Splicing

Heterogeneous Nuclear Ribonucleoprotein A/B
Heterogeneous Nuclear Ribonucleoprotein H3
PREDICTED: RNA-Binding Protein 25
Splicing Factor 3A Subunit 1

Splicing Factor 3B Subunit 3
Splicing Factor U2AF 35 kDa Subunit
Splicing Factor, Proline- And Glutamine-Rich

Cell Cycle

Cytochrome C
E3 SUMO-Protein Ligase PIAS4
E3 Ubiquitin-Protein Ligase TRIM21

Integrin Beta-1 Precursor
PREDICTED: Centromere Protein J
PREDICTED: RNA-Binding Protein 25

Immune Response

PREDICTED: Complement C4-A
PREDICTED: PML-RARA-Regulated Adapter Molecule 1
PREDICTED: Histone-Lysine N-Methyltransferase MLL, Partial PREDICTED: Uncharacterized Protein LOC616065

Translation

Elongation Factor 1-Delta
Eukaryotic Translation Initiation Factor 2 Subunit 1

*

*
*

*
*
*

PREDICTED: Uncharacterized Protein LOC616065
PREDICTED: Vomeronasal Type-1 Receptor 4

The interactors’ biological process GO annotations were manually clustered based on
similarity of the GO names and descriptions. All proteins are to be considered of cellular
origin, unless marked as viral (*).
5.2

Differential Expression of Particular bICP0 Interactors
Previous studies in our lab had examined the differential expression (DE) of

cellular proteins before and after BHV-1 infection (Meyer, unpublished data). 8 cellular
proteins from the bICP0 PPI profile were found to coincide with findings from the DE
study. As seen in Table 5.2, the 8 putative interactors modulated during infection are
primarily involved with mRNA processing, translation, and the cytoskeleton. While most
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interactors (7) were down-regulated, the splicing factor heterogeneous nuclear
ribonucleoprotein H3 was the only one found to be up-regulated during BHV-1 infection.
Table 5.2

Differentially Expressed Proteins within bICP0 PPI Profile

Protein Name1

Biological Process2

Fold
Change

Short Stature Homeobox Protein 2

n/a

-26.44

Brain-Specific Angiogenesis Inhibitor 1Associated Protein 2

Cytoskeleton

-26.42

Elongation Factor 1-Delta

Translation

-25.41

PREDICTED: RNA-Binding Protein 25
PREDICTED: IQ Motif Containing GTPase
Activating Protein 1
Talin-1

mRNA Processing

-3.05

n/a

-2.57

n/a

-1.65

Splicing Factor 3B Subunit 3

mRNA Processing

-1.43*

Heterogeneous Nuclear Ribonucleoprotein H3

mRNA Processing

2.94

1

Protein names are as listed in the database used for MS identification.
Biological process is based upon GO annotation, when available, and manual curation.
*Indicates insignificant fold change based upon a threshold of ±1.5, as recommended by
the IPA software.
2

5.3

Common Protein Domains
In order to identify any common conserved structural and functional domains

(CDs), interactors underwent a batch CD-Search (Marchler-Bauer & Bryant, 2004).
Twenty domain superfamilies common to multiple interactors (threshold of 2 interactors
minimum) were identified as possible points of contact with bICP0 (Table 5.3). These
include domains involved in protein-protein interactions and nucleotide binding, among
others. These common domains could help understand with which domains in a protein
bICP0 is able to interact.
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Table 5.3
Domain
Protein-Protein Interactions

Conserved Domains Common amongst Interactors of bICP0
Interactors with Domain

Description

Myotubularin-Related Protein 10
PH-like:
Pleckstrin homology-like domain

Predicted: Spectrin Beta Chain, Brain 4-Like

Targeting to protein to the appropriate cellular location or interacting with a binding partner. This domain family can bind inositol phosphates.

Talin-1
PREDICTED: Nebulin
SH3:
Src Homology 3 domain superfamily
LRR_4:
Leucine Rich repeats
PDZ:
PSD95, DlgA, and ZO1
RING:
Really Interesting New Gene
Nucleotide Binding

PREDICTED: PML-RARA-Regulated Adapter Molecule 1
Brain-Specific Angiogenesis Inhibitor 1-Associated Protein 2
PREDICTED: Centriolin
Leucine-Rich Repeat-Containing Protein 59
PREDICTED: Protein Shroom2, Partial
PREDICTED: PDZ Domain-Containing Protein 2
E3 Ubiquitin-Protein Ligase TRIM21
*bICP0

Bind to proline-rich ligands with moderate affinity and selectivity, preferentially to PxxP motifs. SH3 domains are less selective and show more diverse specificity compared to
other proline-rich binding domains. They have been shown to bind peptide sequences that lack the PxxP motif.

Short sequence motifs with diverse functions and cellular locations.
Many PDZ domains bind C-terminal polypeptides, though binding to internal (non-C-terminal) polypeptides and even to lipids has been demonstrated. PDZ domain-mediated
interactions may be modulated dynamically through target phosphorylation.
Specialized type of Zn-finger of 40 to 60 residues that binds two atoms of zinc. Probably involved in mediating protein-protein interactions, it has been identified in proteins
with a wide range of functions such as viral replication, signal transduction, and development.

Heterogenous Nuclear Ribonucleoprotein A/B
Heterogenous Nuclear Ribonucleoprotein H3
Splicing Factor U2AF 35 kDa Subunit
RRM_SF:
RNA recognition motif superfamily

Splicing Factor, Proline- And Glutamine-Rich
Zinc Finger Protein 638

Found in proteins involved in post-transcriptional gene expression processes including mRNA and rRNA processing, RNA export, and RNA stability. RRM usually interacts
with ssRNA, but is also known to interact with ssDNA as well as proteins. The RRM domain is found in a variety heterogeneous nuclear ribonucleoproteins (hnRNPs), proteins
implicated in regulation of alternative splicing, and protein components of small nuclear ribonucleoproteins (snRNPs).

PREDICTED: RNA-Binding Protein 25
Nucleolysin TIAR
PREDICTED: Centriolin
PREDICTED: Ninein Isoform 2

DUF1524

This family of uncharacterized proteins contain a conserved HXXP motif. A similar motif is seen in protein families in the His-Me finger endonuclease superfamily which
suggests this family of proteins may also act as endonucleases.

Leucine Zipper Protein 1
Protein Modification
SH3 Domain-Binding Glutamic Acid-Rich-Like Protein 3
Protein Disulfide-Isomerase A5 Precursor

Thioredoxin_like

PKc_like:
Protein Kinases, catalytic domain

PREDICTED: Thioredoxin Domain-Containing Protein 15
Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2
*Serine/Threonine Protein Kinase Us3

The thioredoxin (TRX)-like superfamily functions as a protein disulfide oxidoreductase, altering the redox state of target proteins via the reversible oxidation of their active site
dithiol.

Catalytic domains of serine/threonine-specific and tyrosine-specific protein kinases.

Cytoskeleton
PREDICTED: Spectrin Beta Chain, Brain 4-Like
CH:
Calponin homology

BAR:
Bin/Amphiphysin/Rvs
Ras_like_
GTPase:
Rat sarcoma (Ras)-like superfamily

PREDICTED: Plectin-Like
Filamin-A
PREDICTED: IQ Motif Containing GTPase Activating Protein 1
Brain-Specific Angiogenesis Inhibitor 1-Associated Protein 2
E3 Ubiquitin-Protein Ligase TRIM21
GTP-Binding Protein 2
Ras-Related Protein Rab-1B
PREDICTED: Spectrin Beta Chain, Brain 4-Like

Spectrin

PREDICTED: Plectin-Like

Miscellaneous

Actin-binding domain.

BAR domains form dimers that bind to membranes, induce membrane bending and curvature, and may also be involved in protein-protein interactions.
The Ras superfamily includes the Ras, Rho, Rab, and Sar1/Arf families. This superfamily also includes proteins like the GTP translation factors, Era-like GTPases, and G-alpha
chain of the heterotrimeric G proteins. Members of the Ras superfamily regulate a wide variety of cellular functions: the Ras family regulates gene expression, the Rho family
regulates cytoskeletal reorganization and gene expression, the Rab and Sar1/Arf families regulate vesicle trafficking, and the Ran family regulates nucleocytoplasmic transport
and microtubule organization. The GTP translation factor family regulates initiation, elongation, termination, and release in translation, and the Era-like GTPase family
regulates cell division, sporulation, and DNA replication.
Spectrin repeat. Found in several proteins involved in cytoskeletal structure.

PREDICTED: Keratin, Type II Cytoskeletal 2 Oral
PREDICTED: Centromere Protein J
ApoLp-III_like:
Apolipophorin-III

PREDICTED: Plectin-Like

ApoLp-III increases the lipid carrying capacity of lipophorin by covering the expanding hydrophobic surface resulting from diacylglycerol uptake.

PREDICTED: Cytoskeleton-Associated Protein 4 Isoform 1
PREDICTED: Keratin, Type II Cytoskeletal 2 Epidermal
PREDICTED: Collagen Alpha-3(VI) Chain Isoform 1
FN3:
Fibronectin type 3 domain

Fibronectin Type III Domain-Containing Protein 3B
PREDICTED: Collagen Alpha-3(VI) Chain Isoform 1

Collagen

Collagen Alpha-2(XI) Chain Precursor
PREDICTED: Immunoglobulin-like and Fibronectin Type III Domain-Containing Protein 1like

Ig:
Immunoglobulin

*Envelope Glycoprotein C

LDH_MDH
_like:
lactate dehydrogenase-like, malate
dehydrogenase family
PTZ00249

PREDICTED: Immunoglobulin-Like And Fibronectin Type III Domain-Containing Protein
1-Like

Malate Dehydrogenase, Cytoplasmic
L-Lactate Dehydrogenase A Chain
PREDICTED: Protein Shroom2, Partial
PREDICTED: PML-RARA-Regulated Adapter Molecule 1

Approximately 2% of all animal proteins contain the FN3 repeat, including extracellular and intracellular proteins, membrane spanning cytokine receptors, growth hormone
receptors, tyrosine phosphatase receptors, and adhesion molecules.

Collagens are generally extracellular structural proteins involved in formation of connective tissue structure.
Members of this group are components of immunoglobulin, neuroglia, cell surface glycoproteins (such as T-cell receptors—CD2, CD4, and CD8), and membrane
glycoproteins.
LDH catalyzes the last step of glycolysis in which pyruvate is converted to L-lactate. MDH is one of the key enzymes in the citric acid cycle, facilitating both the conversion of
malate to oxaloacetate and replenishing levels of oxalacetate by reductive carboxylation of pyruvate.
n/a

Conserved domains are grouped according to the broad category of interactions that they
serve (denoted in white). Full descriptions can be obtained from NCBI’s Conserved
Domain Database at http://www.ncbi.nlm.nih.gov/cdd/. All proteins are to be considered
of cellular origin, unless marked as viral (*).
5.4

Pathway Analysis
In order to better understand what cellular metabolic or signaling pathways might

be affected by bICP0, two pathway analyses were performed using the following
programs: QIAGEN’s Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City,
www.qiagen.com/ingenuity) and Search Tool for the Retrieval of Interacting
Genes/Proteins (STRING (Jensen et al., 2009)). IPA and STRING were primarily
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designed for investigating interactions and pathways within the human proteome. The use
of these programs required converting the gene IDs of the bovine proteins in our dataset
to gene IDs of homologs in human, mouse, or other model organisms (Figure 5.1). This
homolog list constituted the input. The pathways identified were thus all characterized in
these other model species. It is important to note that not all proteins in our dataset have a
suitable homolog in one of the model organisms; thus some bovine proteins and all BHV1 proteins were not included in these pathway analyses.

Figure 5.1

Conversion of Bovine Proteins to Homologs in Model Organisms for
Network Analysis.

IPA identified three main networks involving bICP0 interactors (Figures 5.2, 5.3,
and 5.4; Tables 5.4, 5.5, and 5.6). Networks 1 and 2 are primarily involved in the innate
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immune response to infection, with tumor necrosis factor-α (TNF) and IFN at the center.
Network 1 links TNF and inhibitor of NF-κB (IKBKB) to 12 bICP0 interactors (Figure
5.2 and Table 5.4). At least 4 proteins in our dataset (note: all proteins from our PPI
profile are shaded in gray in Figure 5.2) are specifically related to TNF and/or IKBKB
activity. Network 2 involves 12 bICP0 interactors and is focused on TNF receptor
(TNFRSF1A) and interferon-β (IFNB1) (Figure 5.3 and Table 5.5). Modulation of host
innate immune response is essential for efficient viral replication, and this network
suggests possible routes of manipulation by bICP0 via interference with downstream
effectors of TNF and IFN-β signaling. This is plausible given that bICP0 is known to
inhibit IFN-β induction in various ways (Frizzo da Silva, Gaudreault, & Jones, 2011;
Saira et al., 2007, 2009). Interestingly, there is even a direct interaction between 1 of the
bICP0 interactors (PSMD2) and the TNFRSF1A. The third network identified by IPA
included 10 bICP0 interactors and primarily involved proteins related to the DNA
damage response, such as p53 (TP53) and various DNA replication factors (Figure 5.4
and Table 5.6). This is an interesting correlation with research describing ICP0’s
interaction with p53 (Boutell & Everett, 2003) and cyclin D3 (Kalamvoki & Roizman,
2009) to control apoptotic signaling and the cell cycle, respectively. Furthermore, Figure
5.4 even shows 2 direct interactions of bICP0 interactors (HSPH1 and CCT4) with cyclin
D1 (CCND1), as well as KRT14’s direct interaction with TP53.
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Figure 5.2

IPA Network 1: TNF and IKBKB Activation/Signaling

Only proteins found in the bICP0 PPI profile are shaded gray; proteins of particular
interest are marked (*). Dotted lines represent indirect interactions, full lines define
direct interactions. Complete IPA network node and edge legend is located in Appendix
A.
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Table 5.4

Proteins in IPA Network 1: TNF and IKBKB Activation/Signaling
Gene
ADAMTS4
AMPD3
APEX1
ATP1A1
CCL5
CDO1
CTSZ
CYCS
CYP7B1
EMP1
HNRNPAB
HSPE1
IKBKB
IL4
ITPR2
MRPS10
MVK
MYD88
NES
PLD3
PLEC
POU2F1
PPIF
Prl2c4
RABEP2
RBP1
SH3BGRL3
SLC29A1
SNCG
SOD1
SPP1
TLN1
TMEM176B
Tmsb4x
TNF

Protein
A Disintegrin And Metalloproteinase With Thrombospondin Motifs 4 Precursor
Uncharacterized Protein
DNA-(Apurinic Or Apyrimidinic Site) Lyase
Sodium/Potassium-Transporting Atpase Subunit Alpha-1
C-C Motif Chemokine 5
Cysteine Dioxygenase Type 1
Cathepsin Z
Cytochrome C
Uncharacterized Protein
Uncharacterized Protein
Heterogeneous Nuclear Ribonucleoprotein A/B
10 Kda Heat Shock Protein, Mitochondrial
Inhibitor Of Nuclear Factor Kappa-B Kinase Subunit Beta
Interleukin-4
Inositol 1,4,5-Trisphosphate Receptor Type 2
28S Ribosomal Protein S10, Mitochondrial
Mevalonate Kinase
Myeloid Differentiation Primary Response Protein Myd88
Nestin
Phospholipase D3
PREDICTED: Plectin-Like
POU Domain, Class 2, Transcription Factor 1
Peptidyl-Prolyl Cis-Trans Isomerase F, Mitochondrial
Prolactin-2C3
Rab Gtpase-Binding Effector Protein 2
Retinoblastoma-Binding Protein 1
SH3 Domain-Binding Glutamic Acid-Rich-Like Protein 3
Solute Carrier Family 29 Member 1
Gamma-Synuclein
Superoxide Dismutase [Cu-Zn]
Sphingosine-1-Phosphate Phosphatase 1
Talin-1
Transmembrane Protein 176B
Thymosin Beta-4
Tumor Necrosis Factor

*Denotes protein from bICP0 PPI profile.
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*
*
*
*

*
*

*
*
*
*
*

*

*

Figure 5.3

IPA Network 2: IFN-β Induction & Down-Stream Effectors

Only proteins found in the bICP0 PPI profile are shaded gray; proteins of particular
interest are marked (*). Dotted lines represent indirect interactions, full lines define
direct interactions. Complete IPA network node and edge legend is located in Appendix
A.
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Table 5.5

Proteins in IPA Network 2: IFN-β Induction & Down-Stream Effectors
Gene
ACO1
AGL
ALDOA
CDC20
CLIP1
COL6A3
COX6A2
CSN2
DDX3X
ENO1
ESRRA
FBLN2
FLNA
GAPDHS
IDI1
IFNB1
IL2
IQGAP1
ITGB1
LDHA
LDHB
MCM5
MYC
NOS2
PFN1
PSMD2
PYGM
SLC1A5
SLC2A3
STIP1
TCF4
TNFRSF1A
TNNI3
TNNT3
TRIM21

Protein
Aconitate Hydratase, Mitochondrial Precursor
Glycogen Debranching Enzyme
Fructose-Bisphosphate Aldolase A
Cell Division Cycle Protein 20 Homolog
CAP-Gly Domain-Containing Linker Protein 1
PREDICTED: Collagen Alpha-3(VI) Chain Isoform 1
Cytochrome C Oxidase Subunit 6A2, Mitochondrial
Beta-Casein
ATP-Dependent RNA Helicase DDX3X
Alpha-Enolase
Estrogen-Related Receptor Alpha
Fibulin-2
Filamin-A
Glyceraldehyde-3-Phosphate Dehydrogenase, Testis-Specific
Isopentenyl-Diphosphate Delta-Isomerase 1
Interferon Beta
Interleukin-2
Ras-Related Protein Rab-1B
Integrin Beta-1 Precursor
L-Lactate Dehydrogenase A Chain
L-Lactate Dehydrogenase B Chain
DNA Replication Licensing Factor MCM5
Myc Proto-Oncogene Protein
Nitric Oxide Synthase, Inducible
Profilin-1
26S Proteasome Non-ATPase Regulatory Subunit 2
Glycogen Phosphorylase, Muscle Form
Solute Carrier Family 1 Member 5
Solute Carrier Family 2, Facilitated Glucose Transporter Member 3
Stress-Induced-Phosphoprotein 1
Transcription Factor 4
Tumor Necrosis Factor Receptor Superfamily Member 1A
Troponin I, Cardiac Muscle
Troponin T, Fast Skeletal Muscle
E3 Ubiquitin-Protein Ligase TRIM21

*Denotes protein from bICP0 PPI profile.
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Figure 5.4

IPA Network 3: DNA Damage Response

Only proteins found in the bICP0 PPI profile are shaded gray; proteins of particular
interest are marked (*). Dotted lines represent indirect interactions, full lines define direct
interactions. Complete IPA network node and edge legend is located in Appendix A.
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Table 5.6

Proteins in IPA network 3: DNA Damage Response
Gene
ABCE1
AURKA
AURKB
BTG2
CCND1
CCT4
DIAPH3
EIF2S1
FEN1
GMNN
HIPK2
HSPH1
KIAA0101
KRT14
MAP3K1
MAP4K2
MCM4
MCM5
MCM7
mir-34
MSH6
NANOG
PERP
POLH
PRRC2C
PSRC1
RAD51AP1
RB1
SFPQ
TP53
TYMS
UHRF1
YWHAE
YY1
ZNF638

Protein
ATP-Binding Cassette Sub-Family E Member 1
Aurora Kinase A
Aurora Kinase B
Protein BTG2
G1/S-Specific Cyclin-D1
T-Complex Protein 1 Subunit Delta
Protein Diaphanous Homolog 3
Eukaryotic Translation Initiation Factor 2 Subunit 1
Flap Endonuclease 1
Geminin
Homeodomain-Interacting Protein Kinase 2
Heat Shock Protein 105 Kda
PCNA-Associated Factor
Keratin, Type I Cytoskeletal 14
Mitogen-Activated Protein Kinase Kinase Kinase 1
Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2
DNA Replication Licensing Factor MCM4
DNA Replication Licensing Factor MCM5
DNA Replication Licensing Factor MCM7
miRNA-34
DNA Mismatch Repair Protein MSH6
Homeobox Protein NANOG
P53 Apoptosis Effector Related To PMP-22
DNA Polymerase Eta
Protein PRRC2C
Proline/Serine-Rich Coiled-Coil Protein 1
RAD51-Associated Protein 1
Retinoblastoma-Associated Protein
Splicing Factor, Proline- And Glutamine-Rich
Cellular Tumor Antigen P53
Thymidylate Synthase
E3 Ubiquitin-Protein Ligase UHRF1
14-3-3 Protein Epsilon
Transcriptional Repressor Protein YY1
Zinc Finger Protein 638

*Denotes protein from bICP0 PPI profile.

*

*
*
*

*
*
*

*

*

*
*

The STRING analysis identified clusters of proteins interacting together to enact
mRNA processing and splicing, translation, cellular metabolism, and maintenance of the
cytoskeleton (Figure 5.5 and Table 5.7). These biological processes were also highly
represented in the GO analysis (Table 5.1). The STRING visualization of these
interactions evinces a possible manner in which bICP0 could directly interact with just a
few of these molecules and influence the activities of entire clusters—a scenario we
hypothesize as very likely considering both the nature of the co-IP and the vast number of
putative interactors within the bICP0 PPI profile.

60

Figure 5.5

STRING Network: Cellular Processes Vital to Viral Replication

Blue edges denote binding; black edges, reactions; and gray edges, indirect interactions.
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Table 5.7
Gene
ACO2
ACTB
APEX1
BAIAP2
CCT3
CCT4
COL11A2
CYCS
EEF1D
EIF2S1
EIF3I
ENO1
GAPDHS
HNRNPA
B
HSPH1
ITGB1
LDHA
LOC53778
2
LOC78669
9
MDH1
PDHA2
PDHB
PSMC1
PSMC3
PSMC5
PSMD2
SF3A1
SF3A2
SF3A3
SF3B3
STIP1
U2AF1

Proteins in STRING Network
Protein
Aconitate hydratase, mitochondrial Precursor (Aconitase)(EC 4.2.1.3)(Citrate hydro-lyase)
Actin, cytoplasmic 2 (Gamma-actin) [Contains Actin, cytoplasmic 2, N-terminally processed]
DNA-(apurinic or apyrimidinic site) lyase (EC 4.2.99.18)(Apurinic-apyrimidinic endonuclease 1)(AP endonuclease 1)(APEX nuclease)(APEN)
Brain-specific angiogenesis inhibitor 1-associated protein 2 (BAI1-associated protein 2)(BAI-associated protein 2)
T-complex protein 1 subunit gamma (TCP-1-gamma)(CCT-gamma)
T-complex protein 1 subunit delta (TCP-1-delta)(CCT-delta)
Proline/arginine-rich protein
Cytochrome c
Elongation factor 1-delta (EF-1-delta)
Eukaryotic translation initiation factor 2 subunit 1 (Eukaryotic translation initiation factor 2 subunit alpha)(eIF-2-alpha)(EIF-2alpha)(EIF-2A)
Eukaryotic translation initiation factor 3 subunit I (eIF3i)(Eukaryotic translation initiation factor 3 subunit 2)(eIF-3-beta)(eIF3 p36)
Alpha-enolase (EC 4.2.1.11)(2-phospho-D-glycerate hydro-lyase)(Non-neural enolase)(NNE)(Enolase 1)(Phosphopyruvate hydratase)(HAP47)
Glyceraldehyde-3-phosphate dehydrogenase, testis-specific (EC 1.2.1.12)(Spermatogenic glyceraldehyde-3-phosphate dehydrogenase)

*
*

heterogeneous nuclear ribonucleoprotein A/B

*

Heat shock protein 105 kDa (Heat shock 110 kDa protein)
Integrin beta-1 Precursor (Fibronectin receptor subunit beta)(Integrin VLA-4 subunit beta)(CD29 antigen)
L-lactate dehydrogenase A chain (LDH-A)(EC 1.1.1.27)(LDH muscle subunit)(LDH-M)

*
*
*

*
*
*
*
*
*
*
*
*

PREDICTED: Bos taurus misc_RNA (LOC537782), miscRNA
Profilin-1 (Profilin I)

*

Malate dehydrogenase, cytoplasmic (EC 1.1.1.37)(Cytosolic malate dehydrogenase)
pyruvate dehydrogenase (lipoamide) alpha 2
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial Precursor (PDHE1-B)(EC 1.2.4.1)
proteasome 26S ATPase subunit 1
Proteasome 26S ATPase subunit 3 Fragment
26S protease regulatory subunit 8
26S proteasome non-ATPase regulatory subunit 2 (26S proteasome regulatory subunit RPN1)(26S proteasome regulatory subunit S2)(26S
proteasome subunit p97)(Tumor necrosis factor type 1 receptor-associated protein 2)
Splicing factor 3 subunit 1
Splicing factor 3A subunit 2
splicing factor 3a, subunit 3, 60kDa
Splicing factor 3B subunit 3 (Spliceosome-associated protein 130)(SAP 130)(Pre-mRNA-splicing factor SF3b 130 kDa subunit)(SF3b130)
Stress-induced-phosphoprotein 1 (STI1)(Hsc70/Hsp90-organizing protein)(Hop)
Splicing factor U2AF 35 kDa subunit (U2 auxiliary factor 35 kDa subunit)(U2 snRNP auxiliary factor small subunit)

*
*

*Denotes protein from bICP0 PPI profile.

62

*
*

*
*
*

CHAPTER VI
DISCUSSION

6.1

Interactors Related to Previously Known Functions of bICP0
bICP0 functions as a transcription factor, regulator of immune response, and is a

ubiquitin E3 ligase. Based on this knowledge and on a variety of aspects of viral infection
in general, several proteins from our PPI profile caught our attention. While none of the
previously published bICP0 interactors were pulled down in our co-IP, perhaps due to
transient interactions difficult to detect in co-IPs, we find similar proteins in our PPI
profile. It is important to note that we have examined only endogenous protein levels
during infection and have not conducted any overexpression experiments. This could
hinder the detection of some protein-protein interactions. In addition, it is possible that
the reported interactors are not direct, but part of a larger complex that is not particularly
abundant at endogenous levels.
6.1.1

bICP0 is a Transcription Factor
In its capacity as a transcription factor, bICP0 has been reported to interact with

both histone deacetylase-1 (HDAC-1) (Y. Zhang & Jones, 2001) and p300 (a histone
acetyltransferase) (Y. Zhang et al., 2006). These activities, combined with bICP0’s
described function as a promiscuous transactivator and its apparent inability to directly
bind to DNA, have led to the hypothesis that bICP0 indirectly affects gene transcription
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through interaction with chromatin remodeling complexes and perhaps other
transcriptional factors (Clinton Jones & Chowdhury, 2007).
We have found 10 transcription factors based on GO annotations (Table 5.1),
including SFPQ (splicing factor, proline- and glutamine-rich)—whose expression we
found to be induced at higher levels during BHV-1 infection (Figure 4.7). From this list
of 10 transcription factors within bICP0’s interactome, 2 proteins are especially
interesting in the context of BHV-1 infection: histone-lysine N-methyltransferase MLL
(KMT2A) and transactivating tegument protein VP16. KMT2A is a chromatin remodeler
that regulates gene expression through its activities as a histone H3 lysine 4
methyltransferase. Its presence in the bICP0 PPI profile falls in accordance with previous
reports of bICP0’s interaction with chromatin remodeling enzymes HDAC-1 and p300
(Y. Zhang et al., 2006; Y. Zhang & Jones, 2001), whereas bICP0 may use KMT2A to
modify histones, and thereby alter the chromatin landscape to promote or repress certain
genes. Finding tegument protein VP16 was also very interesting since it is the main
transactivator of BHV-1 IE genes (Misra, Walker, Hayes, & Hare, 1995). Furthermore, a
recent study found both VP16 and bICP0 to be expressed in the same neuron at very early
stages of viral reactivation, possibly in order to induce transcription of the other viral
genes (Frizzo da Silva et al., 2013). While the lysate used for our co-IP was from BHV-1
productively-infected cells, the reports mentioned above suggest a possible synergy
between bICP0 and VP16 that may help promote viral gene expression, and therefore it is
not surprising that these two proteins interact.
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6.1.2

bICP0 Regulates Intrinsic and Innate Immune Responses during BHV-1
Infection
bICP0 is well-known for its ability to inhibit interferon-β promoter activity during

BHV-1 infection by ubiquitinating IRF-3 (Saira et al., 2007) and sequestering IRF-7
(Saira et al., 2009), as well as by other less defined methods (Frizzo da Silva et al., 2011).
Interestingly, two E3 ligases involved with the negative regulation of NF-κB transcription
factor activity were co-immunoprecipitated with bICP0: TRIM21 and PIAS4. TRIM21 is
a ubiquitin ligase, like bICP0, and known to down regulate the pro-inflammatory
response, in part, by ubiquitinating IRF-3 and causing its degradation (Higgs et al., 2008).
PIAS4 is a SUMO (small ubiquitin-like modifier) E3 ligase reported to both interact with
IRF-3, IRF-7, and other factors to prevent induction of interferon-β (J. Zhang, Xu, Han,
Wei, & Shu, 2004). Therefore, we hypothesize that it is not coincidental that TRIM21
and PIAS4 co-immunoprecipitated with bICP0, and that bICP0 may use the interaction
with these enzymes to negatively regulate interferon-β promoter induction.
Another interesting cellular protein in the bICP0 PPI profile is eukaryotic
translation initiation factor 2 subunit 1 (eIF2S1), whose phosphorylation by doublestranded RNA-dependent protein kinase (PKR) as part of the interferon-induced signaling
pathway causes cessation of protein translation in the cell (Benedict et al., 2002). In
HSV-1 infection, viral protein ICP34.5 counters this host immune response by causing
the dephosphorylation of eIF2S1. However, ICP34.5 is poorly conserved amongst other
herpesviruses (He, Gross, & Roizman, 1997), and there is no known homolog in BHV-1.
We hypothesize that bICP0 may interact with eIF2S1 in order to fulfill a similar role as
HSV-1’s ICP34.5 to prevent translation shutoff during BHV-1 infection.
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BHV-1 tegument protein VP13/14, more commonly referred to as VP8, is the
most abundantly expressed viral protein in both the virion and infected cell. Distributed
mainly in the nucleus, it has also been observed in the cytoplasm at late point of infection
(van Drunen Littel-van den Hurk, Garzon, van den Hurk, Babiuk, & Tijssen, 1995). It is
believed to both augment nuclear exportation of viral transcripts (Donnelly, Verhagen, &
Elliott, 2007) and aid capsid egress from the nucleus as part of virion maturation (van
Drunen Littel-van den Hurk et al., 1995). While VP8 has been shown to be required for
growth and virulence in the cow (Lobanov et al., 2010), it is also known as a strong
immunogen, causing both humoral and cell-mediated immune responses (van Drunen
Littel-van den Hurk et al., 1995). Based on VP8’s immunogenicity, and in combination
with bICP0’s ability to inhibit interferon response (Henderson, Zhang, & Jones, 2005), it
can be hypothesized that bICP0 might interact with VP8 to silence its antagonistic effect
on the host’s immune response. It is also possible that this interaction is useful at later
times post infection to target bICP0 to the virion. ICP0 has been found in the mature
HSV-1 virion (Loret, Guay, & Lippé, 2008; Delboy, Siekavizza-Robles, & Nicola, 2010).
Preliminary data from our own lab (unpublished) suggest that bICP0 is also present in the
mature virion.
6.2

Interactions Supported by bICP0’s Homology with ICP0
In addition to proteins related to previously reported functions of bICP0, Table

5.1 also lists interactors in accordance with findings from studies on bICP0’s homolog in
HSV-1, ICP0. In other words, these proteins and the processes in which they participate
have not been previously associated with bICP0.
66

6.2.1

Centromere Proteins
Discovering centromere protein-J (CENP-J) and centriolin in our PPI profile were

particularly interesting, because bICP0’s homolog in HSV, ICP0, is known to both colocalize with and cause the subsequent proteasomal degradation of centromere proteins
(CENP) -A, -B, and -C, as well as others on a continually growing list (Boutell & Everett,
2013; R D Everett, Earnshaw, Findlay, & Lomonte, 1999; Gross, Catez, Masumoto, &
Lomonte, 2012; P Lomonte & Morency, 2007; P Lomonte et al., 2001). Thus it would not
be surprising if further analysis revealed degradation of centriolin and CENP-J in the
context of BHV-1 infection, especially since bICP0 has previously been shown to disrupt
centromeres and cause loss of CENP-C in transfected cells (Parkinson & Everett, 2000).
As for how the degradation of centromere proteins might benefit the virus, ICP0’s
targeting of centromeres has been suggested as a mechanism to prevent or reverse
chromatinization of the herpesviral genome, a mechanism specifically pertinent to viral
reactivation from latency (Gross et al., 2012; P Lomonte et al., 2001).
6.2.2

Microtubules
CENP-J is also 1 of the 5 proteins involved in microtubule organization identified

in the bICP0 co-IP; the other 4 proteins are AP-3 complex subunit sigma-1, brain-specific
angiogenesis inhibitor 1-associated protein 2, integrin beta-1 precursor, and profiling-1.
A 2010 study examining the movements of ICP0 in HSV-1 infected cells found an
intriguing association between ICP0 and the dispersal of the microtubule network in the
infected cell’s cytoplasm—an effect for which they found ICP0 to be necessary and
sufficient. Furthermore, mutational studies revealed that the RING domain was required
for microtubule disassembly, although not co-localization. Reorganizing the microtubule
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layout is a common theme employed by many viruses, suggesting that this activity may
be necessary for viral exodus from the host cell (Liu, Schmidt, & Halford, 2010). Upon
viral entry, however, the microtubule network is relied upon for delivery of the
herpesviral capsid to the nucleus for subsequent release and replication of the viral DNA
(Sodeik et al., 1997). In this context, ICP0, which is both present in the HSV-1 tegument
and closely associated with the capsid, has been demonstrated to positively affect the
efficiency of capsid transportation to the nuclear periphery (Delboy & Nicola, 2011;
Delboy et al., 2010). In both cases, ICP0’s association with microtubules appears to aid
viral entry and egress, roles in which bICP0 might similarly participate during BHV-1
infection.
6.3

Novel Interactions
In addition to proteins that are congruent with known activities and functions of

bICP0 and its homolog ICP0, we have identified other proteins involved in apoptosis
regulation and splicing of mRNA transcripts—processes significant during viral
infections.
6.3.1

Apoptosis
From our list in cellular protein interactors (Table 4.2), cytochrome c was

immediately recognized as an interesting finding. As part of the cellular internal
apoptosis signaling pathway, the release of cytochrome c from the mitochondria causes
the formation of the apoptosome and downstream activation of caspase-3. Apoptosis is
not conducive for viral replication, and many viruses have strategies to prevent or delay
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apoptosis, including interfering with cytochrome c release and caspase-3 cleavage
(Benedict et al., 2002).
In addition to cytochrome c, we were also able to co-IP adenylate kinase 2 (AK2),
another mitochondrial protein that has been linked with amplifying intrinsic apoptotic
signaling. AK2 is normally found within the mitochondria, co-localizing with
cytochrome c, but when it is released into the cytoplasm, it complexes with FADD to
cause the activation of caspase-10, which leads to the downstream activation of caspase-3
(Lee et al., 2007).
In the context of BHV-1 infection, bICP0 has been previously reported to both
delay apoptosis and to indirectly induced caspase-3 cleavage during lytic infection.
Neuronal cells transfected with a mutant bICP0 lacking a nuclear localization signal
(which cannot enter the nucleus) showed an increase in cleaved caspase-3 in a dosedependent manner, implying that cytoplasmic mutant bICP0 is more toxic and causes
increased apoptosis than wild-type bICP0 (Henderson et al., 2004). We hypothesize that
bICP0 may interact (directly or indirectly) with cytochrome c and AK2 released from the
mitochondria as a mechanism to delay apoptosis.
6.3.2

Splicing
Another interesting finding from our bICP0 co-IP was the identification of 7

cellular proteins involved in mRNA splicing (Table 5.1) and their associated spliceosome
network (Figure 5.4). Splicing is very important to viral biology since some viral genes
require alternative splicing for expression. In particular, bICP0’s transcript is derived
from alternative splicing of the same transcriptional unit as bICP4 (another BHV-1
transcriptional activator) (Wirth, Vogt, & Schwyzer, 1991). Furthermore, alternative
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splicing may have a role in maintenance of latency, as the latency-related gene (the only
known gene to be transcribed during latency) is known to have multiple, alternativelyspliced transcripts—one of which has been demonstrated to inhibit induction of the
bICP0 promoter during latency (Devireddy, Zhang, & Jones, 2003).
We identified a number of different splicing factors in our bICP0 PPI profile,
some of which are involved in the splicesome complex illustrated in the STRING
network (Figure 5.5). While technical issues prevented confocal microscopy of hnRNP
H3 and SFPQ, we had success with hnRNP A/B. Interestingly, confocal microscopy
revealed a very distinct redistribution of the splicing factor hnRNP A/B in infected cells
compared to uninfected cells (Figure 4.6), where a higher concentration of hnRNP A/B
was seen in the nuclei of infected cells and possibly co-localizing with bICP0. This, in
combination with the 6 other splicing factors co-immunoprecipitated with bICP0 (5 of
which were predicted by STRING to associate and act as 1 splicesome complex) and the
observed increase in SFPQ expression during infection (Figure 4.7), lead us to
hypothesize that bICP0 may influence the cellular mRNA processing machinery in order
to promote viral replication.
6.4

Conclusion
In summary, through co-IP of bICP0 from BHV-1 infected cells we have

generated a PPI profile of 98 cellular and 15 viral putative interactors. Some of these
proteins fit the profile of known functions of bICP0: transcription factor, modulator of
host immune response, and ubiquitin E3 ligase. Concerning bICP0’s role as an ubiquitin
E3 ligase, our lab had previously conducted a study of the differential expression of
cellular proteins during BHV-1 infection, and, interestingly, 6 of the proteins found to be
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interacting with bICP0 were also found to be present at significantly decreased levels
during infection, raising the possibility that bICP0 could also be targeting these for
degradation. Other bICP0 interactors hint at similarities with the homologous ICP0
encoded by HSV-1, particularly in regard to the centromere proteins and disassembly of
microtubules. Lastly, we also identified proteins known to be involved in apoptosis
signaling and mRNA spicing. Of these proteins, further examination found altered
subcellular distributions of cytochrome c and the splicing factor hnRNP A/B, while
another protein involved in both transcription and splicing, SFPQ, was found to be
expressed at higher concentrations during infection.
This is the first successful study to discern the protein interactome of bICP0.
Overall, we have unveiled very interesting interactions that fall in accordance with
previously known functions; furthermore, our results also suggest new, unreported
functions for bICP0. Future work will be geared towards exploring these novel
interactions, it particular cytochrome c and AKs, and it will be interesting to determine
whether bICP0 plays a significant role in mediating the apoptosis signaling pathway.
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